US20100331310A1 - Bicycloamine derivatives - Google Patents

Bicycloamine derivatives Download PDF

Info

Publication number
US20100331310A1
US20100331310A1 US12/867,024 US86702409A US2010331310A1 US 20100331310 A1 US20100331310 A1 US 20100331310A1 US 86702409 A US86702409 A US 86702409A US 2010331310 A1 US2010331310 A1 US 2010331310A1
Authority
US
United States
Prior art keywords
group
alkyl
compound
alkoxy
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/867,024
Other languages
English (en)
Inventor
Fumihiro Ozaki
Motohiro Soejima
Tasuku ISHIDA
Yoshihiko Norimine
Nobuyuki Kurusu
Eriko Doi
Toshihiko Kaneko
Daiju Hasegawa
Kiyoaki Kobayashi
Noboru Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Priority to US12/867,024 priority Critical patent/US20100331310A1/en
Assigned to EISAI R&D MANAGEMENT CO., LTD. reassignment EISAI R&D MANAGEMENT CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KOBAYASHI, KIYOAKI, ISHIDA, TASUKU, NORIMINE, YOSHIHIKO, HASEGAWA, DAIJU, SOEJIMA, MOTOHIRO, DOI, ERIKO, KURUSU, NOBUYUKI, OZAKI, FUMIHIRO, YAMAMOTO, NOBORU, KANEKO, TOSHIHIKO
Publication of US20100331310A1 publication Critical patent/US20100331310A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to bicycloamine derivatives having sodium channel inhibitory action, and particularly 8-azabicyclo[3.2.1]octane or 9-azabicyclo[3.3.1]nonane derivatives or pharmaceutically acceptable salts thereof.
  • Compounds having sodium channel inhibitory action are known to be useful as treatment for various types of neuralgia (for example, postherpetic neuralgia, diabetic neuralgia, HIV-induced neuralgia and the like).
  • neuralgia for example, postherpetic neuralgia, diabetic neuralgia, HIV-induced neuralgia and the like.
  • Compounds having sodium channel inhibitory action include Lidocaine, Carbamazepine, Mexiletine, Amitriptyline and the like, which are already used as therapeutic agents for various types of neuralgia.
  • Lidocaine is used as a treatment for postherpetic neuralgia
  • Carbamazepine is used as a treatment for trigeminal neuralgia.
  • Mexiletine and Lidocaine are effective as analgesics (see Non-patent documents 1-3, for example).
  • Carbamazepine used as an anticonvulsant, is effective as a treatment for manic-depressive psychosis (Non-patent document 5).
  • Lidocaine and Mexiletine are effective for various symptoms of multiple sclerosis (Non-patent document 6).
  • Lidocaine is effective as a treatment for premature ejaculation (Non-patent document 7).
  • Carbamazepine and Oxocarbazepine used as anticonvulsants also have somnolent action (Non-patent documents 8 and 9), and sodium channel inhibitors can be used as treatments for insomnia.
  • sodium channel inhibitors are thus effective as treatments for the diseases mentioned above, sodium channels are also present in non-neuronal tissue such as in the muscles and heart, such that they exhibit side-effects when systemically administered.
  • Nav1.8 is a tetrodotoxin (TTX)-resistant sodium channel localized in the small neurons of the dorsal root ganglion (C-fibers) that are associated with nerve sensation, and it is referred to as sensory neuron specific sodium channel (SNS) SCN10A or PN3 (Non-patent documents 12 and 13). It has been reported that Nav1.8 knockout mice have an increased nociception threshold for mechanical stimulation (Non-patent document 14), and that administration of antisense DNA for Nav1.8 to neurogenic pain or inflammatory pain models attenuates hyperesthesia and dysesthesia.
  • TTX tetrodotoxin
  • SNS sensory neuron specific sodium channel
  • Nav1.8 inhibitors are promising as drugs capable of exhibiting analgesic effects against diseases of neurogenic pain including pain, numbness, burning sensation and dull pain, or nociceptive pain, in which C-fibers are involved. Also, since Nav1.8 is not expressed in non-neuronal tissue or central nerve, drugs that selectively inhibit Nav1.8 are considered to have potential as drugs with no side-effects in non-neuronal tissue or central nerve.
  • This compound has an inhibitory activity against sodium channels in cultured rat hippocampus but its inhibitory activity against ectopic firing is described as inadequate.
  • No bicycloamine compounds other than the 3-azabicyclo[3.3.1]nonane derivative are disclosed in the patent document.
  • 8-azabicyclo[3.2.1]octane derivatives and 9-azabicyclo[3.3.1]nonane derivatives having sodium channel inhibitory action are still unknown.
  • Patent document 1 WO01/053288
  • Patent document 2 US20050020564
  • Patent document 3 WO03/037274
  • Patent document 4 WO03/037890
  • Patent document 5 WO03/037900
  • Patent document 6 WO06/082354
  • Patent document 7 WO06/113875
  • Patent document 8 WO06/132192
  • Patent document 9 WO07/052,123
  • Patent document 10 WO07/083,239
  • Non-patent document 1 Sindrup et al., Pain, 83:389-400, 1999
  • Non-patent document 2 Kalso et al., Eur. J.
  • Non-patent document 3 Kingery et al., Pain, 73:123-139, 1997
  • Non-patent document 4 Yaman et al., Pharmacol. Ther., 90:21-34, 2001
  • Non-patent document 5 Obrocea et al., Biol. Psychiatry, 51:253-260, 2002
  • Non-patent document 6 Sakurai et al., J. Neurol.
  • Non-patent document 7 Atikeler et al., Andrologia, 34:356-359, 2002
  • Non-patent document 8 Nieto-Barrera et al., Epilepsy, 46:145-155, 2002
  • Non-patent document 9 Wellington et al., CNS Drugs, 15:137-163, 2001
  • Non-patent document 10 Taylor et al., Trends Pharmacol.
  • Non-patent document 11 Stutzmann et al., 31st Annual Meeting of Society for Neuroscience, Abstract 199, 16, 2001
  • Non-patent document 12 Akopian et al., Nature, 379:257-262, 1996
  • Non-patent document 13 Rabert et al., Pain, 78:107-114, 1998
  • Non-patent document 14 Akopian et al., Nat. Neurosci., 2:541-548, 1999
  • the present invention provides the following [1]-[21].
  • Group D1 consists of halogen, hydroxy, C 1-6 alkyl and C 1-6 alkoxy.
  • Group C1 consists of halogen, hydroxy, C 1-6 alkoxy, oxo and C 1-6 alkyl.
  • Group E2 consists of halogen, cyano, C 1-6 alkyl, halo-C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkoxy and C 2-7 acyl.
  • the compounds represented by formula (I) of the invention have excellent sodium channel inhibitory action, and the invention can therefore provide novel bicycloamine compounds and pharmaceutically acceptable salts thereof that have high utility as drugs when comprehensively considered from the viewpoint of pharmacological activity, as well as novel pharmaceutical compositions comprising the same.
  • the compounds of the invention and pharmaceutical compositions comprising the same can exhibit excellent therapeutic effect for diseases for which sodium channel inhibition is effective, and are promising as therapeutic agents and analgesics for various kinds of neuralgia (for example, diabetic neuralgia, HIV-induced neuralgia, postherpetic neuralgia, trigeminal neuralgia, stump pain, post-spinal cord injury pain, thalamic pain and post-apoplectic pain), neuropathy, epilepsy, insomnia, premature ejaculation and the like.
  • neuralgia for example, diabetic neuralgia, HIV-induced neuralgia, postherpetic neuralgia, trigeminal neuralgia, stump pain, post-spinal cord injury pain, thalamic pain and post-apoplectic pain
  • neuropathy for example, diabetic neuralgia, HIV-induced neuralgia, postherpetic neuralgia, trigeminal neuralgia, stump pain, post-spinal cord injury pain, thalamic pain
  • the structural formulas for the compounds will show only one specific isomer for convenience, but the invention includes all isomers such as geometric isomers, optical isomers based on asymmetric carbons, stereoisomers, tautomers and the like, that are implied by the compound structures, as well as isomer mixtures thereof, and the compounds may therefore be any of the isomers or mixtures thereof, without being limited to the formulas shown for convenience.
  • the compounds of the invention may have asymmetric carbon atoms in the molecule and thus exist as optically active or racemic forms, all of which are included without limitations according to the invention.
  • Polymorphic crystals may also exist, and there may be used any simple crystal form or crystal mixture without any restrictions, while the compounds of the invention also include both anhydrate and hydrate forms.
  • so-called metabolites produced by in vivo decomposition of the compounds of the invention are also included within the scope of the claims of the invention.
  • halogen represents fluorine, chlorine, bromine and iodine.
  • C 1-6 alkyl represents an alkyl group of straight or branched chain having a carbon number of 1 to 6, which is a monovalent group derived by removing one hydrogen from aliphatic hydrocarbon having a carbon number of 1 to 6, and as specific examples there may be mentioned methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 1-butyl, 2-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 2,2-dimethyl-1-propyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2-methyl-3-pentyl, 2-
  • halo-C 1-6 alkyl represents “C 1-6 alkyl” as defined above wherein 1-5 hydrogen atoms have been replaced with “halogen” as defined above, and as specific examples there may be mentioned fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, 1-fluoroethyl, 2-fluoroethyl, 2-chloroethyl, 1,2-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 3-chloropropyl, 2-fluoro-2-propyl, 4-fluorobutyl, 5-fluoropentyl and 6-fluorohexyl.
  • hydroxy-C 1-6 alkyl represents “C 1-6 alkyl” as defined above wherein 1-2 hydrogen atoms have been replaced with hydroxy, and as specific examples there may be mentioned hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 2-hydroxy-2-propyl, 1,2-dihydroxypropyl, 1,3-dihydroxypropyl, 2,3-dihydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl and 6-hydroxyhexyl.
  • C 2-6 alkenyl represents an alkenyl group of straight or branched chain having a carbon number of 2 to 6, with one double bond, and as specific examples there may be mentioned ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), 1-butenyl, 2-butenyl, 3-butenyl, pentenyl and hexenyl.
  • C 3-8 cycloalkyl represents a cyclic aliphatic hydrocarbon group having a carbon number of 3 to 8, and as specific examples there may be mentioned cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • C 3-8 cycloalkylmethyl represents a methyl group wherein “C 3-8 cycloalkyl” as defined above is bonded thereto, and as specific examples there may be mentioned cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl and cyclooctylmethyl.
  • C 1-6 alkylene represents a divalent group derived by removing any hydrogen from “C 1-6 alkyl” as defined above, and as specific examples there may be mentioned methylene, 1,2-ethylene, 1,1-ethylene, 1,3-propylene, tetramethylene, pentamethylene and hexamethylene.
  • C 2-6 alkylene refers to C2-6 groups among “C 1-6 alkylene” groups as defined above, and as specific examples there may be mentioned 1,2-ethylene, 1,1-ethylene, 1,3-propylene, tetramethylene, pentamethylene and hexamethylene.
  • C 2-6 alkenylene represents a divalent group derived by removing any hydrogen from “C 2-6 alkenyl” as defined above, and as specific examples there may be mentioned vinylene, propenylene, butenylene, pentenylene and hexenylene.
  • cyclopropane-1,2-dimethylene represents a divalent group derived by removing one hydrogen from each of the two methyl groups of 1,2-dimethylcyclopropane.
  • C 1-6 alkoxy represents an oxy group bonded to “C 1-6 alkyl” as defined above, and as specific examples there may be mentioned methoxy, ethoxy, 1-propyloxy, 2-propyloxy, 2-methyl-1-propyloxy, 2-methyl-2-propyloxy, 1-butyloxy, 2-butyloxy, 1-pentyloxy, 2-pentyloxy, 3-pentyloxy, 2-methyl-1-butyloxy, 3-methyl-1-butyloxy, 2-methyl-2-butyloxy, 3-methyl-2-butyloxy, 2,2-dimethyl-1-propyloxy, 1-hexyloxy, 2-hexyloxy, 3-hexyloxy, 2-methyl-1-pentyloxy, 3-methyl-1-pentyloxy, 4-methyl-1-pentyloxy, 2-methyl-2-pentyloxy, 3-methyl-2-pentyloxy, 4-methyl-2-pentyloxy, 2-methyl-3-pentyloxy, 3-methyl-3-pentyloxy
  • halo-C 1-6 alkoxy represents “C 1-6 alkoxy” as defined above wherein 1-5 hydrogen atoms have been replaced by “halogen” as defined above, and as specific examples there may be mentioned fluoromethoxy, difluoromethoxy, trifluoromethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2-chloroethoxy, 1,2-difluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 1-fluoropropyloxy, 2-fluoropropyloxy, 3-fluoropropyloxy, 3-chloropropyloxy, 2-fluoro-2-propyloxy, 4-fluorobutyloxy, 5-fluoropentyloxy and 6-fluorohexyloxy.
  • C 1-6 alkoxy-C 1-6 alkyl represents“C 1-6 alkyl” as defined above wherein “C 1-6 alkoxy” as defined above is bonded thereto, and as specific examples there may be mentioned methoxymethyl, 1-methoxyethyl, 2-methoxyethyl, 1-methoxypropyl, 2-methoxypropyl, 3-methoxypropyl, 2-methoxy-2-propyl, (1-propyloxy)methyl, (2-propyloxy)methyl, 1-(1-propyloxy)ethyl, 2-(1-propyloxy)ethyl, 1-(2-propyloxy)ethyl, 2-(2-propyloxy)ethyl, 1-(1-propyloxy)propyl, 2-(1-propyloxy)propyl, 3-(1-propyloxy)propyl, 2-(1-propyloxy)-2-propyl, 1-(2-propyloxy)propyl, 2-(2-propyloxy
  • C 1-6 alkyleneoxy or “oxy-C 1-6 alkylene” represents a divalent group derived by further removing any hydrogen from “C 1-6 alkoxy” as defined above, and as specific examples there may be mentioned methyleneoxy, ethyleneoxy, trimethyleneoxy, tetramethyleneoxy, pentamethyleneoxy and hexamethyleneoxy.
  • C1-6 alkylthio represents a thio group bonded to “C1-6 alkyl” as defined above, and as specific examples there may be mentioned methylthio, ethylthio, 1-propylthio, 2-propylthio, butylthio and pentylthio.
  • C 1-6 alkylenethio or “thio-C 1-6 alkylene” represents a divalent group derived by further removing any hydrogen from “C 1-6 alkylthio” as defined above, and as specific examples there may be mentioned methylenethio, ethylenethio, trimethylenethio and tetramethylenethio.
  • C 1-6 alkyleneoxy-C 1-6 alkylene represents a divalent group wherein two “C 1-6 alkylene” groups as defined above bonded to an oxy group, and as specific examples there may be mentioned methyleneoxymethylene, methyleneoxyethylene, methyleneoxypropylene, ethyleneoxymethylene, ethyleneoxyethylene, ethyleneoxypropylene, propyleneoxymethylene, propyleneoxyethylene and propyleneoxypropylene.
  • C 1-6 alkyleneamino or “amino-C 1-6 alkylene” represents a divalent group wherein “C 1-6 alkylene” as defined above is bonded to an amino group, and as specific examples there may be mentioned methyleneamino, ethyleneamino and propyleneamino.
  • C 1-6 alkyleneaminocarbonyl or “carbonylamino-C 1-6 alkylene” represents a divalent group wherein a carbonyl group is bonded to the amino group of “C 1-6 alkyleneamino” as defined above, and as specific examples there may be mentioned methyleneaminocarbonyl, ethyleneaminocarbonyl and propyleneaminocarbonyl.
  • C 1-6 alkylsulfonyl represents a sulfonyl group wherein “C 1-6 alkyl” as defined above is bonded thereto, and as specific examples there may be mentioned methylsulfonyl, ethylsulfonyl, 1-propylsulfonyl, 2-propylsulfonyl, butylsulfonyl and pentylsulfonyl.
  • C 2-7 acyl represents a carbonyl group wherein “C 1-6 alkyl” as defined above is bonded thereto, and as specific examples there may be mentioned acetyl, propionyl, isopropionyl, butyryl, isobutyryl, valeryl, isovaleryl and pivaloyl.
  • C 1-6 alkoxycarbonyl represents a carbonyl group wherein “C 1-6 alkoxy” as defined above is bonded thereto, and as specific examples there may be mentioned methoxycarbonyl, ethoxycarbonyl, 1-propyloxycarbonyl and 2-propyloxycarbonyl.
  • C 1-6 alkylcarbonylamino represents a carbonylamino group wherein “C 1-6 alkyl” as defined above is bonded thereto, and as specific examples there may be mentioned methylcarbonylamino, ethylcarbonylamino and propylcarbonylamino.
  • C 1-6 alkoxycarbonylamino represents a carbonylamino group wherein “C 1-6 alkoxy” as defined above is bonded thereto, and as specific examples there may be mentioned methoxycarbonylamino, ethoxycarbonylamino and propyloxycarbonylamino.
  • C 1-6 alkylsulfonylamino represents an amino group wherein “C 1-6 alkylsulfonyl” as defined above is bonded thereto, and as specific examples there may be mentioned methylsulfonylamino, ethylsulfonylamino and propylsulfonylamino.
  • C 1-6 alkoxyimino represents an imino group wherein “C 1-6 alkoxy” as defined above is bonded thereto, and as specific examples there may be mentioned methoxyimino, ethoxyimino and propylimino
  • amino optionally having one or two C 1-6 alkyl represents amino, mono-C 1-6 alkylamino and di-C 1-6 alkylamino, where C 1-6 alkyl has the same definition as above.
  • mono-C 1-6 alkylamino there may be mentioned methylamino, ethylamino, 1-propylamino, 2-propylamino, 2-methyl-1-propylamino, 2-methyl-2-propylamino, 1-butylamino, 2-butylamino, 1-pentylamino, 2-pentylamino, 3-pentylamino, 2-methyl-1-butylamino, 3-methyl-1-butylamino, 2-methyl-2-butylamino, 3-methyl-2-butylamino, 2,2-dimethyl-1-propylamino, 1-hexylamino, 2-hexylamino, 3-hexylamino, 2-methyl-1-pentylamino, 3-methyl-1-pentylamino, 2-
  • di-C 1-6 alkylamino there may be mentioned N,N-dimethylamino, N,N-diethylamino, N,N-di-n-propylamino, N,N-di-i-propylamino, N,N-di-n-butylamino, N,N-di-i-butylamino, N,N-di-s-butylamino, N,N-di-t-butylamino, N-ethyl-N-methylamino, N-n-propyl-N-methylamino, N-i-propyl-N-methylamino, N-n-butyl-N-methylamino, N-i-butyl-N-methylamino, N-s-butyl-N-methylamino and N-t-butyl-N-methylamino.
  • C 6-14 aryl represents an aromatic hydrocarbon ring group having a carbon number of 6 to 14, and as specific examples there may be mentioned phenyl, naphthyl and anthryl.
  • C 6-10 aryl represents an aromatic hydrocarbon ring group having a carbon number of 6 to 10, and as specific examples there may be mentioned phenyl and naphthyl.
  • C 7-11 aralkyl represents an alkyl group of straight-chain or branched having a carbon number of 1 to 5 wherein “C 6-10 aryl” as defined above is bonded thereto, and as specific examples there may be mentioned benzyl and naphthylmethyl.
  • heteroatom represents nitrogen atom, oxygen atom or sulfur atom.
  • 5- to 6-membered aromatic heterocycle represents an aromatic ring having 5 or 6 atoms composing the ring and containing one or more heteroatoms among the atoms composing the ring, and as specific examples there may be mentioned thiophene, furan, pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole, triazole, pyrazole, furazan, thiadiazole, oxadiazole, pyridine, pyridazine, pyrimidine, pyrazine and triazine.
  • 5- to 6-membered aromatic heterocyclic group represents a monovalent group derived by removing one hydrogen at any position from “5- to 6-membered aromatic heterocycle” as defined above.
  • 5- to 6-membered heterocycle represents a non-aromatic monocycle having 5 or 6 atoms composing the ring, containing 1-4 heteroatoms among the atoms composing the ring, optionally containing 1-2 double bonds in the ring and optionally containing 1-3 carbonyl groups in the ring, and as specific examples there may be mentioned pyrrolidine, piperidine, tetrahydrofuran, tetrahydropyran, morpholine, thiomorpholine, piperazine, thiazolidine, dioxane, imidazoline, thiazoline, 2,4-dihydro-[1,2,4]-triazol-3-one, 3H-pyrimidin-4-one, 1H-pyrimidine-2,4-dione, 1H-[1,3,5]-triazine-2,4-dione and tetrazolone.
  • 5- to 6-membered aromatic heterocyclic group represents a monovalent or divalent group derived by removing 1 or 2 hydrogen from any position of “5- to 6-membered aromatic heterocycle” as defined above.
  • 8- to 11-membered fused heterocycle represents a fused non-aromatic ring having 8-11 atoms composing the ring, containing 2-5 heteroatoms among the atoms composing the ring, optionally containing 1-2 double bonds in the ring and optionally containing 1-3 carbonyl groups in the ring, and as specific examples there may be mentioned 1,2,4-triazol-3-one-containing fused heterocycle such as:
  • R 6 represents hydrogen or C 1-6 alkyl, 1,3,5-triazine-2,4-dione-containing fused heterocycle such as:
  • R 9 represents hydrogen or C 1-6 alkyl, pyrimidin-4-one-containing fused heterocycle such as:
  • R 12 represents hydrogen or C 1-6 alkyl
  • R 13 and R 14 independently represent hydrogen, C 1-6 alkyl or C 6-10 aryl.
  • 8- to 11-membered fused heterocyclic group represents a monovalent group derived by removing one hydrogen at any position from “8- to 11-membered fused heterocycle” as defined above.
  • 9- to 11-membered benzo-fused heterocycle represents a bicyclic ring where a 5- to 7-membered aromatic or non-aromatic heterocycle is fused with a benzene ring, and as specific examples there may be mentioned indole, isoindole, indazole, chromene, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthylidine, phthalazine, purine, pteridine, thienofuran, imidazothiazole, benzofuran, benzothiophene, benzoxazole, benzothiazole, benzothiadiazole, benzimidazole, imidazopyridine, pyrrolopyridine, pyrrolopyrimidine, pyridopyrimidine, benzoazepine and benzodiazepine, among which indole, quinoline and benzothiophene are preferred.
  • 9- to 11-membered benzo-fused heterocyclic group represents a monovalent or divalent group derived by removing 1 or 2 hydrogen from any position of “9- to 11-membered benzo-fused heterocycle” as defined above.
  • substituent means optionally having 1-3 substituents selected as desired from the substituents in the relevant substituent group.
  • Q represents ethylene or trimethylene, and preferably ethylene.
  • R 1 , R 2 and R 3 each independently represents hydrogen, halogen or hydroxy, or C 1-6 alkyl or C 1-6 alkoxy each optionally having one or more substituents selected from Group A.
  • R 1 , R 2 and R 3 there may be mentioned hydrogen for R 1 and R 2 , and hydrogen, methyl or methoxymethyl for R 3 .
  • R 1 , R 2 and R 3 are all hydrogen.
  • X 1 represents cyclopropane-1,2-dimethylene, or C 1-6 alkylene or C 2-6 alkenylene each optionally having one or more substituents selected from Group B.
  • X 1 there may be mentioned C 2-6 alkylene optionally having one or more substituents selected from Group B1.
  • C 2-6 alkylene optionally having one or more substituents selected from the group consisting of halogen, amino, acetamide, methoxyacetamide, methanesulfonylamide, hydroxy, oxo, cyano, C 1-6 alkyl, hydroxy-C 1-6 alkyl, halo-C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl and C 1-6 alkoxy.
  • X 2 represents C 1-6 alkylene, C 1-6 alkyleneoxy, oxy-C 1-6 alkylene, C 1-6 alkylenethio, thio-C 1-6 alkylene, C 1-6 alkyleneoxy-C 1-6 alkylene, C 2-6 alkenylene, oxycarbonyl, carbonyloxy, C 1-6 alkyleneamino, amino-C 1-6 alkylene, aminocarbonyl, carbonylamino, C 1-6 alkyleneaminocarbonyl, carbonylamino-C 1-6 alkylene, oxycarbonylamino, aminocarbonyloxy or ureylene each optionally having one or more substituents selected from Group C.
  • X 2 represents C 1-6 alkyleneoxy
  • the C 1-6 alkylene portion of X 2 is bonded to 8-azabicyclo[3.2.1]octane or 9-azabicyclo[3.3.1]nonane (hereinafter also referred to as “azabicyclo”)
  • the oxy portion is bonded to A 2 .
  • X 2 represents oxy-C 1-6 alkylene
  • the oxy portion of X 2 is bonded to azabicyclo and the C 1-6 alkylene portion of X 2 is bonded to A 2 .
  • X 2 is C 1-6 alkyleneamino
  • the C 1-6 alkylene portion of X 2 is bonded to azabicyclo and the amino portion is bonded to A 2 .
  • X 2 is amino-C 1-6 alkylene
  • the amino portion of X 2 is bonded to azabicyclo and the C 1-6 alkylene portion of X 2 is bonded to A 2 .
  • X 2 may be in either the endo form or the exo form with regard to 8-azabicyclo[3.2.1]octane or 9-azabicyclo[3.3.1]nonane, but preferably in the endo form.
  • X 2 there may be mentioned C 1-6 alkylene, C 1-6 alkyleneoxy or oxy-C 1-6 alkylene each optionally having one or more substituents selected from Group C1.
  • X 2 there may be mentioned C 1-6 alkylene, C 1-6 alkyleneoxy or oxy-C 1-6 alkylene each optionally having one or more substituents selected from the group consisting of halogen, hydroxy, C 1-6 alkoxy, oxo and C 1-6 alkyl.
  • a 1 represents a 5- to 6-membered heterocyclic group or a 8- to 11-membered fused heterocyclic group each optionally having one or more substituents selected from Group D.
  • R 4 represents hydrogen or C 1-6 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 3-8 cycloalkylmethyl, C 6-10 aryl, C 7-11 aralkyl or a 5- to 6-membered aromatic heterocyclic group each optionally having one or more substituents selected from Group D1, and
  • R 5 represents hydrogen, a halogen, hydroxy, or amino optionally having one or two C 1-6 alkyl, or C 1-6 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 3-8 cycloalkylmethyl, C 1-6 alkylthio, C 1-6 alkylsulfonyl, C 6-10 aryl, C 7-11 aralkyl or a 5- to 6-membered aromatic heterocyclic group each optionally having one or more substituents selected from Group D1,
  • R 6 represents hydrogen or C 1-6 alkyl
  • R 7 represents hydrogen or C 1-6 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 3-8 cycloalkylmethyl, C 6-10 aryl, C 7-11 aralkyl or a 5- to 6-membered aromatic heterocyclic group each optionally having one or more substituents selected from Group D1, and
  • R 8 represents hydrogen, halogen, hydroxy, or amino optionally having one or two C 1-6 alkyl, or C 1-6 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 3-8 cycloalkylmethyl, C 1-6 alkylthio, C 1-6 alkylsulfonyl, C 6-10 aryl, C 7-11 aralkyl or a 5- to 6-membered aromatic heterocyclic group each optionally having one or more substituents selected from Group D1,
  • R 9 represents hydrogen or C 1-6 alkyl
  • R 10 represents hydrogen or C 1-6 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 3-8 cycloalkylmethyl, C 6-10 aryl, C 7-11 aralkyl or a 5- to 6-membered aromatic heterocyclic group each optionally having one or more substituents selected from Group D1, and
  • R 11a , R 11b and R 11c each independently represents hydrogen, halogen, hydroxy, or amino optionally having one or two C 1-6 alkyl, or C 1-6 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 3-8 cycloalkylmethyl, C 1-6 alkylthio, C 1-6 alkylsulfonyl, C 6-10 aryl, C 7-11 aralkyl or a 5- to 6-membered aromatic heterocyclic group each optionally having one or more substituents selected from Group D1,
  • R 12 represents hydrogen or C 1-6 alkyl
  • R 13 and R 14 each independently represent hydrogen, C 1-6 alkyl or C 6-10 aryl.
  • R 4 and R 5 have the same definitions as above, groups represented by the formula optionally having one or more substituents group selected from Group D1:
  • R 6 has the same definition as above,
  • R 7 and R 8 have the same definitions as above,
  • R 9 has the same definition as above.
  • R 4 and R 5 have the same definitions as above,
  • R 7 and R 8 have the same definitions as above.
  • a 2 represents C 3-8 cycloalkyl, C 6-14 aryl, a 5- to 6-membered aromatic heterocyclic group or a 9- to 11-membered benzo-fused heterocyclic group each optionally having one or more substituents selected from Group E.
  • a 2 there may be mentioned phenyl, thienyl, benzothienyl and naphthyl each optionally having one or more substituents selected from Group E2.
  • a 2 there may be mentioned phenyl and thienyl each optionally having one or more substituents selected from Group E2.
  • Y 1 and Y 2 each independently represents hydrogen, halogen, hydroxy, C 1-6 alkyl, halo-C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, C 1-6 alkoxy or halo-C 1-6 alkoxy.
  • Group A is the group consisting of halogen, hydroxy and C 1-6 alkoxy.
  • Group B is the group consisting of halogen, hydroxy, oxo, cyano, amino, C 1-6 alkyl, halo-C 1-6 alkyl, hydroxy-C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylcarbonylamino, C 1-6 alkoxycarbonylamino, C 1-6 alkylsulfonylamino, hydroxyimino and C 1-6 alkoxyimino.
  • Group B1 is the group consisting of halogen, amino, acetamide, methoxyacetamide, methanesulfonylamide, hydroxy, oxo, cyano, C 1-6 alkyl, hydroxy-C 1-6 alkyl, halo-C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl and C 1-6 alkoxy.
  • Group B2 is the group consisting of halogen and hydroxy.
  • Group C is the group consisting of halogen, hydroxy, C 1-6 alkoxy, oxo and C 1-6 alkyl.
  • Group C1 is the group consisting of halogen, hydroxy, C 1-6 alkoxy, oxo and C 1-6 alkyl.
  • Group D is the group consisting of halogen, hydroxy and amino optionally having one or two C 1-6 alkyl, and C 1-6 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 3-8 cycloalkylmethyl, C 1-6 alkylthio, C 1-6 alkylsulfonyl, C 6-10 aryl, C 7-11 aralkyl and a 5- to 6-membered aromatic heterocyclic group each optionally having one or more substituents selected from Group D1.
  • Group D1 is the group consisting of halogen, hydroxy, C 1-6 alkyl and C 1-6 alkoxy.
  • Group E is the group consisting of halogen, cyano, hydroxy, C 1-6 alkyl, halo-C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkoxy and C 2-7 acyl, and C 6-10 aryl, a 5- to 6-membered heterocyclic group and a 5- to 6-membered aromatic heterocyclic group each optionally having one or more substituents selected from Group E1.
  • Group E1 is the group consisting of halogen, C 1-6 alkyl, halo-C 1-6 alkyl, C 1-6 alkoxy and halo-C 1-6 alkoxy.
  • Group E2 is the group consisting of halogen, cyano, C 1-6 alkyl, halo-C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkoxy and C 2-7 acyl, and phenyl, furyl, pyridyl, pyrazinyl, pyrrolidinyl, piperidinyl and morpholinyl each optionally having one or more substituents selected from Group E3.
  • Group E3 is the group consisting of halogen, C 1-6 alkyl, halo-C 1-6 alkyl, C 1-6 alkoxy and halo-C 1-6 alkoxy.
  • a “pharmaceutically acceptable salt” as referred to throughout the present specification is not particularly restricted so long as it is formed with a compound of the invention and is pharmaceutically acceptable, and as examples there may be mentioned inorganic acid salts, organic acid salts, inorganic base salts, organic base salts and acidic or basic amino acid salts.
  • inorganic acid salts there may be mentioned hydrochloride, hydrobromide, sulfate, nitrate, phosphate and the like
  • organic acid salts there may be mentioned acetate, succinate, fumarate, maleate, tartrate, citrate, lactate, stearate, benzoate, methanesulfonate, p-toluenesulfonate, oxalate and the like.
  • alkali metal salts such as sodium salt and potassium salt
  • alkaline earth metal salts such as calcium salt and magnesium salt
  • aluminum salt such as calcium salt and magnesium salt
  • ammonium salt and the like alkali metal salts such as sodium salt and potassium salt
  • alkaline earth metal salts such as calcium salt and magnesium salt
  • aluminum salt such as aluminum salt, ammonium salt and the like.
  • acidic amino acid salts there may be mentioned aspartate, glutamate and the like
  • basic amino acid salts there may be mentioned arginine salt, lysine salt, ornithine salt and the like.
  • n an integer of 0-4.
  • Boc represents a tert-butoxycarbonyl group.
  • L 1 and L 2 represent chlorine, bromine or iodine
  • L 3 represents a leaving group such as methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or p-nitrobenzenesulfonyloxy
  • L 4 represents a leaving group such as methanesulfonyloxy, p-toluenesulfonyloxy or p-nitrobenzenesulfonyloxy
  • L 5 represents a leaving group such as chlorine, bromine, p-toluenesulfonyloxy or m-nitrobenzenesulfonyloxy.
  • Met 1 represents the formula —SnR M 3 or —B(OR M ) 2 , wherein R M represents hydrogen, C 1-6 alkyl, phenyl or the like, and Met 2 represents lithium, the formula —Mg—Br or the like.
  • P 1 represents a protecting group such as tert-butyldimethylsilyl, tert-butyldiphenylsilyl or benzyl.
  • T 1 represents nitrogen or CH
  • T 2 represents sulfur or the formula —NR T —, wherein R T represents hydrogen or C 1-6 alkyl.
  • Ts represents p-toluenesulfonyl.
  • X represents chlorine or bromine
  • X 3 represents a group wherein a methylene group has been removed from X 1 , X 4 and X 5 represent C 1-4 alkylene, X 6 represents a bond or C 1-6 alkylene, and X 7 represents C 1-6 alkylene.
  • Y 3 represents hydrogen, C 1-6 alkyl, C 1-6 alkoxy, fluorine or the like
  • Y 4 represents pyridyl, pyrazinyl, furyl or the like
  • Y 5 represents morpholino, pyridyl, pyrazinyl, furyl or the like
  • Y 6 represents methanesulfonyl, trifluoromethanesulfonyl, p-toluenesulfonyl, p-nitrobenzenesulfonyl or the like.
  • Z 1 and Z 2 represent C 1-6 alkyl, C 7-11 aralkyl or the like
  • Z 3 represents methanesulfonyl, p-toluenesulfonyl, p-nitrobenzenesulfonyl or the like
  • Z 4 and Z 5 represent hydrogen, C 1-6 alkyl, C 7-11 aralkyl or the like
  • Z 6 represents methyl or tert-butoxycarbonyl.
  • a 1 , A 2 , X 1 , X 2 , Q, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 have the same definitions as above.
  • room temperature used in the following description refers to a temperature around 15-30° C.
  • Production Process A is a process in which a compound (a-1) is used as starting material to produce a compound (I) or compound (Ia) according to the invention.
  • Compound (a-1) may be a commercially available material, or it may be produced by a process known to those skilled in the art from a commercially available material according to the method described in [Production Process E] or [Production Process F] below.
  • Compound (a-5) and compound (a-7) may be commercially available materials, or they may be produced by a process known to those skilled in the art from commercially available materials according to the method described in [Production Process G] below.
  • Compound (d-32) is the general formula for compounds (d-4), (d-4-a), (d-8), (d-18), (d-21), (d-23), (d-27), (d-30), (d-31), (d-46) described in [Production Process D] below, and compound (d-32) and compound (d-34) may be produced by processes known to those skilled in the art from commercially available materials according to the method described in [Production Process D].
  • Step A-1 is a step in which compound (a-1) and compound (a-2) are subjected to Mitsunobu reaction to obtain compound (a-3).
  • This reaction may be carried out under the same conditions as commonly employed for Mitsunobu reaction (for example, the conditions described in O. Mitsunobu, Synthesis, 1 (1981), D. L. Hughes, Organic Reactions, 42, 335 (1992)).
  • the reaction is conducted using a phosphine derivative such as triphenylphosphine and an azodicarboxylic acid diester such as diethyl azodicarboxylate or diisopropyl azodicarboxylate.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as examples there may be used tetrahydrofuran, benzene, toluene and N,N-dimethylformamide.
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to room temperature.
  • Step A-2 is a step in which compound (a-3) is subjected to hydrolysis under acidic conditions to obtain compound (a-4).
  • reaction may be carried out under the same conditions as commonly employed for hydrolysis of acetal compounds (for example, the conditions described in T. W. Green and P. G. M. Wuts, “Protective Groups in Organic Synthesis, Third Edition”, John Wiley & Sons (1999), p. 297-307).
  • the acid used for this step may be any commonly employed acid, and for example, it may be an acid such as hydrogen chloride, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, trifluoroacetic acid, formic acid or the like, or an acidic ion exchange resin such as Dowex 50W-X8 or Amberlyst-15.
  • the reaction solvent is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as examples there may be used methanol, ethanol, acetone, tetrahydrofuran, 1,4-dioxane, water, and mixtures of the foregoing.
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to the reflux temperature of the solvent.
  • Step A-3 is a step in which compound (a-4) and compound (d-32) are subjected to reductive amination reaction to obtain compound (I).
  • the reaction may be carried out under the same conditions as commonly used for reductive amination reaction of carbonyl compounds and amine compounds.
  • the reduction reaction used for this step is not particularly restricted, and there may be mentioned reductive amination reaction with reducing agents such as borane, boron hydride complexes and formic acid, and catalytic reduction reaction under a hydrogen atmosphere using metal catalysts.
  • Compound (d-32) may be used in free form or as a salt, and preferably hydrochloride or hydrobromide of compound (d-32) is used.
  • boron hydride complexes there may be used sodium borohydride, sodium cyanoborohydride and sodium triacetoxyborohydride.
  • the solvent is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as specific examples there may be mentioned methanol, ethanol, tetrahydrofuran, dichloromethane and 1,2-dichloroethane.
  • the reaction may be carried out in the copresence of an acid for more favorable results, such as increased yield.
  • an acid there are no particular restrictions on such an acid, and it may be a mineral acid such as hydrochloric acid, an organic acid such as acetic acid, or a Lewis acid such as zinc chloride, boron trifluoride-diethyl ether complex or titanium (IV) tetraisopropoxide.
  • the reaction temperature is not particularly restricted but will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ice-cold to room temperature.
  • the solvent is not particularly restricted so long as it does not inhibit the reaction, and an excess of formic acid may even be used as the solvent.
  • the reaction temperature is not particularly restricted but will normally be from 50° C. to the reflux temperature of the solvent.
  • high-temperature heating at 150-250° C. with a sealed pressure-resistant container can produce satisfactory results such as a shortened reaction time.
  • the solvent used for catalytic reduction reaction under a hydrogen atmosphere is not particularly restricted so long as it does not inhibit the reaction, and methanol, ethanol, tetrahydrofuran, 1,4-dioxane, ethyl acetate may be mentioned.
  • metal catalysts for the reaction there may be mentioned palladium on carbon, palladium hydroxide on carbon, platinum oxide, Raney nickel and the like.
  • the reaction conditions are not particularly restricted and may be a temperature between room temperature and the reflux temperature of the solvent and a pressure of between atmospheric pressure and 150 atm, and preferably a temperature from room temperature to 60° C. and a pressure from atmospheric pressure to 5 atm.
  • the reaction may be carried out in the copresence of an acid for more favorable results, such as increased yield.
  • mineral acids such as hydrochloric acid and organic acids such as acetic acid are preferred.
  • Step A-4 is a step in which compound (a-1) and compound (a-5) are subjected to nucleophilic substitution reaction to obtain compound (a-6).
  • compound (a-1) may be reacted with a base to form an anion, which is then reacted with compound (a-5) to obtain compound (a-6).
  • Compound (a-5) will normally be used at about 1 equivalent to an excess, and preferably 3-10 equivalents, with respect to compound (a-1).
  • the solvent for the reaction is not particularly restricted so long as it does not inhibit the reaction, and a suitable base may be reacted at 1 equivalent to an excess, in an organic solvent such as diethyl ether, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide or dimethyl sulfoxide.
  • a suitable base may be reacted at 1 equivalent to an excess, in an organic solvent such as diethyl ether, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide or dimethyl sulfoxide.
  • bases used there may be mentioned sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like.
  • the reaction temperature is not particularly restricted but will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ice-cold to 100° C.
  • Step A-5 is a step in which compound (a-6) and compound (d-32) are subjected to nucleophilic substitution reaction to obtain a compound of formula (I).
  • reaction may be carried out under the same conditions as commonly employed for reaction between secondary amines and halogenated compounds (for example, the conditions described in Y. Hiraki, T. Terada, Y. Okaji, T. Yamazaki, Tetrahedron Letters, 31, 4755 (1990)).
  • Compound (d-32) may be used in free form or as a salt.
  • the solvent used for the reaction in this step is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as examples there may be mentioned methanol, ethanol, propanol, tetrahydrofuran, benzene, toluene, xylene, acetonitrile, dichloromethane, chloroform, N,N-dimethylformamide and dimethyl sulfoxide.
  • the reaction temperature will normally be from room temperature to the reflux temperature of the solvent, and is preferably from room temperature to 100° C.
  • a base is not particularly restricted so long as it does not inhibit the reaction, and as examples there may be mentioned sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium methoxide, potassium tert-butoxide, triethylamine, diisopropylethylamine and diazabicycloundecene.
  • Step A-6 is a step in which compound (a-1) and compound (a-7) are subjected to nucleophilic substitution reaction to obtain compound (a-8).
  • compound (a-1) may be reacted with a base to form an anion, which is then reacted with compound (a-7) to obtain compound (a-8).
  • the solvent for the reaction is not particularly restricted so long as it does not inhibit the reaction, and a suitable base may be reacted at 1 equivalent to an excess, in an organic solvent such as diethyl ether, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide or dimethyl sulfoxide.
  • a suitable base there may be mentioned sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like.
  • the reaction temperature is not particularly restricted but will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ice-cold to 100° C.
  • Step A-7 is a step in which the protecting group for the hydroxyl of compound (a-8) is deprotected to obtain compound (a-9).
  • the reaction may be carried out under the same conditions as commonly employed for silyl group deprotecting reaction (for example, the conditions described in T. W. Green and P. G. M. Wuts, “Protective Groups in Organic Synthesis, Third Edition”, John Wiley & Sons (1999), p. 113-148).
  • silyl group deprotecting reaction for example, the conditions described in T. W. Green and P. G. M. Wuts, “Protective Groups in Organic Synthesis, Third Edition”, John Wiley & Sons (1999), p. 113-148.
  • tetra-n-butylammonium fluoride may be reacted therewith in an organic solvent such as tetrahydrofuran or hydrochloric acid reacted therewith in ethanol, to obtain compound (a-9).
  • the solvent used for the reaction is not particularly restricted so long as it does not inhibit the reaction, but dichloromethane, methanol, ethanol, propanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane or the like is preferred. Addition of acetic acid can often produce satisfactory results such as increased yield.
  • the reaction may be carried out under the same conditions as commonly employed for benzyl group deprotecting reaction (for example, the conditions described in T. W. Green and P. G. M. Wuts, “Protective Groups in Organic Synthesis, Third Edition”, John Wiley & Sons (1999), p. 76-86). Specifically, for example, it may be carried out by a catalytic reduction process under a hydrogen atmosphere, using palladium on carbon, palladium hydroxide on carbon or the like as the catalyst in an organic solvent such as ethanol.
  • the solvent used for the reaction is not particularly restricted so long as it does not inhibit the reaction, and there may be mentioned methanol, ethanol, propanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane and the like.
  • the reaction conditions are not particularly restricted and may be a temperature between room temperature and the reflux temperature of the solvent and a pressure of between atmospheric pressure and 150 atm, and preferably a temperature from room temperature to 60° C. and a pressure from atmospheric pressure to 5 atm.
  • Step A-8 is a step in which compound (a-9) and compound (a-10) are reacted to obtain compound (a-11).
  • the reaction may be carried out under the same conditions as commonly employed for conversion of hydroxyl to leaving groups such as p-toluenesulfonyloxy (for example, the conditions described in Y. Yoshida, Y. Sakakura, N. Aso, S. Okada, and Y. Tanabe, Tetrahedron, 55, 2183 (1999)).
  • leaving groups such as p-toluenesulfonyloxy
  • compound (a-9) may be reacted with methanesulfonyl chloride, p-toluenesulfonyl chloride, p-nitrobenzenesulfonyl chloride or the like to produce compound (a-11).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as specific examples there may be mentioned dichloromethane, chloroform, tetrahydrofuran, toluene, xylene, acetonitrile, N,N-dimethylformamide and the like.
  • the reaction temperature will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ⁇ 78° C. to room temperature.
  • the reaction is preferably carried out in the presence of a base.
  • the base used is not particularly restricted so long as it does not inhibit the reaction, and as preferred examples there may be mentioned sodium carbonate, potassium carbonate, triethylamine, diisopropylethylamine, pyridine and the like. Preferred results such as increased yield may be obtained if the reaction is conducted in the presence of trimethylammonium chloride.
  • Step A-9 is a step in which compound (a-11) and compound (d-32) are subjected to nucleophilic substitution reaction to obtain a compound of formula (I).
  • This step may be carried out under the same conditions as [Step A-5] described above.
  • Step A-10 is a step in which compound (a-1) and compound (a-12) are subjected to nucleophilic substitution reaction to obtain compound (a-14).
  • the reaction may be carried out under the same conditions as commonly employed for reaction between amide compounds and halogenated compounds or sulfonic acid esters (for example, the conditions described in K. Ogawa, Y. Matsushita, Chemical and Pharmaceutical Bulletin, 40, 2442 (1992)).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as examples there may be mentioned methanol, ethanol, propanol, tetrahydrofuran, benzene, toluene, xylene, acetonitrile, dichloromethane, chloroform, N,N-dimethylformamide, dimethyl sulfoxide and the like.
  • the reaction is preferably carried out in the presence of a base.
  • a base is not particularly restricted so long as it does not inhibit the reaction, and as preferred examples there may be mentioned sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium methoxide, potassium tert-butoxide, triethylamine, diisopropylethylamine, diazabicycloundecene and the like.
  • the reaction temperature will normally be from ice-cold to the reflux temperature of the solvent, and is preferably from ice-cold to 50° C.
  • Favorable results such as increased yield may also be achieved by addition of sodium iodide, benzyltri-n-butylammonium iodide, tetra-n-butylammonium iodide or the like.
  • Step A-11 is a step in which compound (a-14) and compound (d-32) are reacted to obtain a compound of formula (Ia).
  • reaction may be carried out under the same conditions as commonly employed for reaction between epoxy compounds and amine compounds (for example, the conditions described in K. Kulig, U. Holzgrabe, B. Malawska, Tetrahedron: Asymmetry, 12, 2533 (2001)).
  • Compound (d-32) may be used in free form or as a salt.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as examples there may be mentioned methanol, ethanol, propanol, tetrahydrofuran, benzene, toluene, xylene, acetonitrile, dichloromethane, chloroform, N,N-dimethylformamide, dimethyl sulfoxide and the like.
  • a base is not particularly restricted so long as it does not inhibit the reaction, and as preferred examples there may be mentioned sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium methoxide, potassium tert-butoxide, triethylamine, diisopropylethylamine, diazabicycloundecene and the like.
  • the reaction temperature will normally be from ice-cold to the reflux temperature of the solvent, and is preferably from room temperature to 100° C.
  • Step A-12 is a step in which compound (a-1) and compound (d-34) are subjected to Mitsunobu reaction to obtain a compound of formula (I).
  • This step may be carried out under the same conditions as [Step A-1] described above.
  • Production Process B is a process in which a compound (b-1) is used as starting material to produce any of compounds (Ib-1) to (Ib-8) according to the invention.
  • Compound (b-1) may be produced according to the method for compound (Ia) described in [Production Process A] above.
  • Step B-1 is a step in which compound (b-1) is reacted with a fluorinating agent to obtain compound (Ib-1).
  • the reaction may be carried out under the same conditions as commonly employed for conversion of hydroxyl to fluorine (for example, the conditions described in M. Hudliky, Organic Reactions, 35, 513 (1988)).
  • fluorinating agents there may be mentioned dimethylaminosulfur-trifluoride, hydrogen fluoride, sulfur tetrafluoride, (2-chloro-1,1,2-trifluoroethyl)diethylamine, 1,1,2,3,3,3-hexafluoro-1-diethylaminopropane, 2,2-difluoro-1,3-dimethylimidazolidine, [bis(2-methoxyethyl)amino]sulfur trifluoride, difluorotriphenylphosphorane, trifluorodiphenylphosphorane and the like, among which dimethylaminosulfur-trifluoride is preferred.
  • the solvent used for the reaction is not particularly restricted so long as it does not inhibit the reaction, and as examples there may be mentioned 1,4-dioxane, tetrahydrofuran, dichloromethane, 1,2-dichloroethane, chloroform and the like.
  • the reaction temperature is not particularly restricted and the reaction may be conducted at a temperature between ⁇ 78° C. and room temperature.
  • Step B-2 is a step in which compound (b-1) and compound (b-2) are subjected to nucleophilic substitution reaction to obtain a compound of formula (Ib-2).
  • This step may be carried out under the same conditions as [Step A-6] described for [Production Process A] above.
  • Step B-3 is a step in which compound (b-1) is subjected to oxidation reaction to obtain compound (Ib-3).
  • reaction may be carried out under the same conditions as commonly employed for oxidation from secondary alcohol compounds to ketone compounds (for example, the conditions described in A. J. Mancuso and D. Swern, Synthesis, 165 (1981)).
  • the method for oxidizing the secondary alcohol to a ketone may be, for example, (a) a method using a metal salt such as chromic acid, (b) Swern oxidation using DMSO (dimethyl sulfoxide), or a modified form of the method, (c) a method using a ruthenium oxide (tetrapropylammonium perruthenate), or (d) a method using hypervalent iodine.
  • the solvent used for the Swern oxidation reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and dimethyl sulfoxide, acetone, dichloromethane, chloroform or the like may be used, for example.
  • the reaction temperature is not particularly restricted and the reaction may normally be conducted at a temperature between ⁇ 78° C. and room temperature.
  • Step B-4 is a step in which compound (Ib-3) and compound (b-4) are reacted to obtain compound (Ib-4).
  • the reaction may be carried out under the same conditions as commonly employed for synthesis of oximes from ketones (for example, the conditions described in P. R. Dave, M. Ferraro, H. L. Ammon and C. S. Choi, Journal of Organic Chemistry, 55, 4459 (1990)).
  • the solvent is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as specific examples there may be used methanol, ethanol, propanol and pyridine.
  • Compound (b-4) may be used in free form or as a salt, and preferably a hydrochloride or hydrobromide of compound (b-4) is used.
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to the reflux temperature of the solvent, and is preferably from room temperature to the reflux temperature of the solvent.
  • Favorable results in the reaction, such as increased yield, can be obtained by addition of a base.
  • the base is not particularly restricted so long as it does not inhibit the reaction, and there may be mentioned as preferable sodium carbonate, potassium carbonate, sodium acetate, potassium acetate and the like.
  • Step B-5 is a step in which compound (Ib-3) and compound (b-5) are subjected to reductive amination reaction to obtain compound (Ib-5).
  • the reaction in this step may be carried out under the same conditions as [Step A-3] described for [Production Process A] above.
  • Step B-6 is a step in which compound (Ib-3) and TosMIC (tosylmethylisocyanide) (b-6) are reacted to obtain compound (Ib-6).
  • the reaction may be carried out under the same conditions as commonly employed for synthesis of nitriles from ketones (for example, the conditions described in Organic Synthesis Coll. Vol., 6, 41 (1988)).
  • the solvent is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as specific examples there may be used solvents such as methanol, ethanol, propanol, tert-butanol, 1,2-dimethoxyethane and the like, or mixtures thereof.
  • the reaction is preferably carried out in the presence of a base.
  • bases there may be mentioned sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like.
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to the reflux temperature of the solvent, and is preferably from room temperature to the reflux temperature of the solvent.
  • Step B-7 is a step in which compound (Ib-5a) and compound (b-7) or compound (b-8) are reacted in the presence of a base to obtain compound (Ib-7).
  • the reaction may be carried out under the same conditions as commonly employed for synthesis of amides from amines (for example, the conditions described in T. W. Green and P. G. M. Wuts, “Protective Groups in Organic Synthesis, Third Edition”, John Wiley & Sons (1999), p. 550-561).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as examples there may be mentioned methanol, ethanol, propanol, tetrahydrofuran, benzene, toluene, xylene, acetonitrile, dichloromethane, chloroform, N,N-dimethylformamide, dimethyl sulfoxide and the like.
  • the reaction is preferably carried out in the presence of a base.
  • a base is not particularly restricted so long as it does not inhibit the reaction, and as preferred examples there may be mentioned sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, potassium methoxide, potassium tert-butoxide, triethylamine, diisopropylethylamine, diazabicycloundecene and the like.
  • the reaction temperature will normally be from ice-cold to the reflux temperature of the solvent, and is preferably from ice-cold to room temperature.
  • Step B-8 is a step in which compound (Ib-5a) and compound (b-9) are reacted in the presence of a base to obtain compound (Ib-8).
  • reaction in this step may be carried out under the same conditions as [Step B-7] described above.
  • Production Process C is a process for production of compound (Ic-1), compound (Ic-2), compound (Ic-4), compound (Ic-6) and compound (Ic-8) according to the invention.
  • Compound (Ic-3), compound (Ic-5) and compound (Ic-7) used as starting materials may be produced according to the method described in [Production Process A] above.
  • Compound (d-34) may be produced by a process known to those skilled in the art from a commercially available material according to the method described in [Production Process D] above.
  • Step C-1 is a step in which compound (c-1) and compound (d-34) are subjected to Mitsunobu reaction to obtain compound (c-2).
  • This step may be carried out under the same conditions as [Step A-1] described for [Production Process A] above.
  • Step C-2 is a step in which compound (c-2) and compound (c-3) are reacted to obtain compound (Ic-1).
  • reaction may be carried out under the same conditions described in the literature, such as in H. Usui, Y. Watanabe, M. Kanao, Journal of Heterocyclic Chemistry, 30, 551 (1993), for example.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as examples there may be mentioned tetrahydrofuran, benzene, toluene, xylene, acetonitrile, dichloromethane, chloroform, N,N-dimethylformamide, dimethyl sulfoxide and the like.
  • the reaction temperature will normally be from ice-cold to the reflux temperature of the solvent, and is preferably from room temperature to the reflux temperature of the solvent.
  • Step C-3 is a step in which compound (Ic-1) and compound (b-2) are subjected to nucleophilic substitution reaction to obtain compound (Ic-2).
  • This step may be carried out under the same conditions as [Step A-4] described for [Production Process A] above.
  • Step C-4 is a step in which compound (Ic-3) is debenzylated by catalytic reduction to obtain a compound of general formula (Ic-4).
  • the reaction may be carried out under the same conditions as commonly employed for debenzylation under a hydrogen atmosphere (for example, the conditions described in T. W. Green and P. G. M. Wuts, “Protective Groups in Organic Synthesis, Third Edition”, John Wiley & Sons (1999), p. 579-581).
  • the solvent used for the reaction is not particularly restricted so long as it does not inhibit the reaction, and methanol, ethanol, tetrahydrofuran, 1,4-dioxane, ethyl acetate may be mentioned.
  • metal catalysts for the reaction there may be mentioned palladium on carbon, palladium hydroxide on carbon, platinum oxide, Raney nickel and the like.
  • the reaction conditions are not particularly restricted and may be a temperature between room temperature and the reflux temperature of the solvent and a pressure of between atmospheric pressure and 150 atm, and preferably a temperature from room temperature to 60° C. and a pressure from atmospheric pressure to 5 atm.
  • the reaction may be carried out in the copresence of an acid for more favorable results, such as increased yield.
  • mineral acids such as hydrochloric acid and organic acids such as acetic acid are preferred.
  • Step C-5 is a step in which compound (Ic-5) is fluorinated to obtain compound (Ic-6).
  • the reaction in this step may be carried out under the same conditions as [Step B-1] described for [Production Process B] above.
  • Step C-6 is a step in which compound (Ic-7) is fluorinated to obtain compound (Ic-8).
  • the reaction in this step may be carried out under the same conditions as [Step B-1] described for [Production Process B] above.
  • the starting materials used for [Production Process D] may be commercially available materials, or they may be produced by methods known to those skilled in the art from commercially available materials.
  • Step D-1 is a step in which compound (d-1) and compound (d-2) are subjected to nucleophilic substitution reaction to obtain compound (d-3).
  • compound (d-1) may be reacted with a base to form an anion, which is then reacted with compound (d-2) to obtain compound (d-3).
  • Compound (d-2) is usually used at 1-5 equivalents with respect to compound (d-1).
  • the solvent for the reaction is not particularly restricted so long as it does not inhibit the reaction, and a suitable base may be reacted at 1 equivalent to an excess, in an organic solvent such as diethyl ether, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, dimethyl sulfoxide or the like.
  • a suitable base there may be mentioned sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like.
  • the reaction temperature is not particularly restricted but will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ice-cold to 100° C.
  • Step D-2 is a step in which Z 6 in compound (d-3) is eliminated to obtain compound (d-4).
  • the reaction may be carried out under the same conditions as commonly employed for deprotecting reaction (for example, the conditions described in T. W. Green and P. G. M. Wuts, “Protective Groups in Organic Synthesis, Third Edition”, John Wiley & Sons (1999), p. 518-525).
  • the solvent for the reaction is not particularly restricted so long as it does not inhibit the reaction, and the reaction may be conducted with a suitable acid such as hydrogen chloride, hydrochloric acid, sulfuric acid, trifluoroacetic acid, p-toluenesulfonic acid or the like in an organic solvent such as diethyl ether, tetrahydrofuran, 1,4-dioxane, acetone, ethyl acetate or the like, or in a mixture of water and an organic solvent.
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to the reflux temperature of the solvent, and is preferably from ice-cold to room temperature.
  • the reaction may be carried out under the same conditions as commonly employed for deprotecting reaction (for example, the conditions described in J. H. Cooley and E. J. Evain, Synthesis, 1 (1989)).
  • 1-chloroethyl chloroformate and methanol may be reacted therewith in that order in a solvent such as 1,2-dichloroethane, toluene or the like.
  • the reaction temperature is not particularly restricted but will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ice-cold to the reflux temperature of the solvent.
  • Step D-3 is a step in which compound (d-5) and compound (d-6) are subjected to Mitsunobu reaction to obtain compound (d-7).
  • reaction in this step may be carried out under the same conditions as [Step A-1] described for [Production Process A] above.
  • Step D-4 is a step in which Z 6 in compound (d-7) is eliminated to obtain compound (d-8).
  • the reaction in this step may be carried out under the same conditions as [Step D-2] described above.
  • Step D-5 is a step in which compound (d-5) and compound (d-9) are reacted to obtain compound (d-7).
  • reaction may be carried out under the same conditions as described in Martina Wolter, Gero Nordmann, Gabriel E. Job, and Stephen L. Buchwald, Organic Letters, 4, 973 (2002), for example.
  • compound (d-5) may be reacted with compound (d-9) in the presence of a copper salt, 1,10-phenanthroline and a base, to obtain compound (d-7).
  • the copper salt used for the reaction is preferably copper(I) iodide.
  • the base is preferably cesium carbonate.
  • the reaction may be carried out without a solvent, or toluene, xylene or the like may be used.
  • the reaction temperature is not particularly restricted but will normally be from room temperature to the reflux temperature of the solvent.
  • Step D-6 is a step in which compound (d-1) and compound (d-10) are reacted to obtain compound (d-3a).
  • the reaction in this step may be carried out under the same conditions as [Step D-1] described above.
  • Step D-7 is a step in which compound (d-3a) is reacted with an organometallic compound (d-11) or morpholine in the presence of a transition metal catalyst to obtain compound (d-3b).
  • This reaction may be carried out under conditions commonly employed for coupling reaction using transition metals (for example, Suzuki coupling reaction, Stille coupling reaction or the like).
  • reaction using an organic boron reagent as the organometallic compound are described in Tetrahedron: Asymmetry, 16, 529 (2005) and Organic Letters, 6, 277 (2004), and an example of reaction using an organic tin reagent is described in Tetrahedron, 61, 4129 (2005).
  • organometallic catalyst used for the reaction there are no particular restrictions on the organometallic catalyst used for the reaction, and as preferred examples there may be mentioned tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, bis(tert-butylphosphine)palladium(0), palladium(II) acetate and the like.
  • organometallic compounds there are also no particular restrictions on organometallic compounds, and as preferred examples there may be mentioned organic tin reagents such as aryl tri-n-butyltins, and organic boron reagents such as arylboric acids.
  • organic tin reagents such as aryl tri-n-butyltins
  • organic boron reagents such as arylboric acids.
  • the solvent used for the reaction is not particularly restricted so long as it does not inhibit the reaction, and as preferred examples there may be mentioned benzene, toluene, xylene, N,N-dimethylformamide, 1-methyl-2-pyrrolidone, tetrahydrofuran, 1,4-dioxane, acetonitrile, propionitrile and the like.
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to the reflux temperature of the solvent, and is preferably, for example, from room temperature to the reflux temperature of the solvent.
  • the reaction may be carried out in the copresence of a base for more favorable results, such as increased yield.
  • a base there are no particular restrictions on the base used for the reaction, and there may be mentioned as preferable bases such as sodium carbonate, potassium carbonate, cesium carbonate and potassium phosphate, or their aqueous solutions, and triethylamine
  • organometallic catalyst used for the reaction there are no particular restrictions on the organometallic catalyst used for the reaction, and as preferred examples there may be mentioned dichlorobis(tri-o-tolylphosphine)palladium(II), [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, bis(tert-butylphosphine)palladium(0), palladium(II) acetate and tris(dibenzylideneacetone)palladium(0).
  • a ligand such as BINAP (2,2′-bis(diphenylphosphino)-1,1′-binaphthyl) or DPPF (1,1′-bis(diphenylphosphino)ferrocene) can smooth progress of the reaction.
  • the reaction is preferably carried out in the copresence of a base.
  • bases such as sodium tert-butoxide, potassium phosphate and lithium bis(trimethylsilyl)amide.
  • the solvent used for the reaction is not particularly restricted so long as it does not inhibit the reaction, and as preferred examples there may be mentioned benzene, toluene, xylene, N,N-dimethylformamide, 1-methyl-2-pyrrolidone, tetrahydrofuran, 1,4-dioxane and the like.
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to the reflux temperature of the solvent, and is preferably, for example, from room temperature to the reflux temperature of the solvent.
  • Step D-8 is a step in which Z 6 in compound (d-3b) is eliminated to obtain compound (d-4-a).
  • the reaction in this step may be carried out under the same conditions as [Step D-2] described above.
  • Step D-9 is a step in which compound (d-12) and compound (d-13) are condensed using a condensation agent to obtain compound (d-14).
  • reaction may be carried out under the same commonly employed conditions described in the literature cited below: for example, J. S. Ward and L. Merritt, Journal of Heterocyclic Chemistry, 27, 1709 (1990).
  • the solvent for the reaction is not particularly restricted so long as it does not inhibit the reaction, and as examples there may be mentioned tetrahydrofuran, 1,4-dioxane, ethyl acetate, methyl acetate, dichloromethane, chloroform, N,N-dimethylformamide, toluene, xylene and the like.
  • condensation agents there may be mentioned CDI (N,N′-carbonyldiimidazole), Bop (1H-1,2,3-benzotriazol-1-yloxy(tris(dimethylamino))phosphonium hexafluorophosphate), WSC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), DCC(N,N′-dicyclohexylcarbodiimide), diethylphosphoryl cyanide and the like. If necessary, 1 equivalent to a large excess of an organic base such as triethylamine and pyridine may also be added.
  • an organic base such as triethylamine and pyridine may also be added.
  • the reaction temperature will normally be from ice-cold to the reflux temperature of the solvent.
  • Step D-10 is a step in which compound (d-14) and an organometallic compound (d-15) are reacted to obtain compound (d-16).
  • the reaction may be carried out under the same conditions as commonly employed for reaction between amide compounds and organometallic reagents to obtain ketone compounds (for example, the conditions described in S. Nahm and S. M. Weinreb, Tetrahedron Letters, 22, 3825 (1981)).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as examples there may be mentioned diethyl ether, tetrahydrofuran, 1,4-dioxane and the like.
  • the reaction temperature is not particularly restricted and the reaction may normally be conducted at a temperature between ⁇ 78° C. and room temperature.
  • Compound (d-15) used in this step may be a commercially available material, or it may be produced by a known process from commercially available materials.
  • the compound when Met 2 is lithium, the compound may be produced under the same conditions as commonly employed for reacting commercially available starting materials with alkyllithium reagents such as n-butyllithium or sec-butyllithium to obtain organic lithium reagents (for example, the conditions described in J. C. H. Hwa and H. Sims, Organic Synthesis, V, 608 (1973)).
  • alkyllithium reagents such as n-butyllithium or sec-butyllithium to obtain organic lithium reagents (for example, the conditions described in J. C. H. Hwa and H. Sims, Organic Synthesis, V, 608 (1973)).
  • the compound When Met 2 is the formula —Mg—Br, the compound may be produced under the same conditions as commonly employed for reaction of commercially available starting materials with magnesium to obtain Grignard reagents (for example, the conditions described in N. A. Nelson and J. C. Wollensak, Journal of American Chemical Society, 80, 662 (1958)).
  • Step D-11 is a step in which the double bond of compound (d-16) is reduced to obtain compound (d-17).
  • the reaction may be carried out under the same conditions as commonly employed for catalytic reduction reaction of unsaturated ketone compounds to saturated ketone compounds under a hydrogen atmosphere (for example, the conditions described in R. L. Augustine, Journal of Organic Chemistry, 23, 1853 (1958)).
  • the catalyst used for the reaction is preferably palladium on carbon, palladium hydroxide on carbon or platinum oxide.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as examples there may be mentioned methanol, ethanol, 2-propanol and ethyl acetate.
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to 100° C.
  • the hydrogen pressure will normally be from atmospheric pressure to 5 atm.
  • Step D-12 is a step in which methyl of compound (d-17) is eliminated to obtain compound (d-18).
  • the reaction may be carried out under the same conditions as commonly employed for deprotection of methyl (for example, the conditions described in J. H. Cooley and E. J. Evain, Synthesis, 1 (1989)).
  • 1-chloroethyl chloroformate and methanol may be reacted therewith in that order in a solvent such as 1,2-dichloroethane or toluene.
  • the reaction temperature is not particularly restricted but will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ice-cold to the reflux temperature of the solvent.
  • Step D-13 is a step in which carbonyl of compound (d-17) is reduced to obtain compound (d-19).
  • the reaction may be carried out under conditions known to those skilled in the art and commonly employed for reduction of ketones to alcohols. For example, it may be conducted under the same conditions as described in H. C. Brown, S. Krishnamurthy, Tetrahedron, 35, 567 (1979).
  • the reducing agent used for the reaction is preferably sodium borohydride or potassium borohydride.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as examples there may be mentioned methanol, ethanol and 2-propanol.
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to the reflux temperature of the solvent.
  • Step D-14 is a step in which compound (d-19) is dehydrated to obtain compound (d-20).
  • the reaction may be carried out under acidic conditions or under the same conditions as employed for dehydration reaction of alcohols (for example, the conditions described in A. Luxenburger, Tetrahedron, 59, 6045 (2003)).
  • the solvent used in the reaction is not particularly restricted so long as it does not inhibit the reaction, and acetone, toluene, xylene or the like may be used.
  • the acid used for the reaction may be, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, oxalic acid, p-toluenesulfonic acid or the like.
  • the acid may be used at normally 1 equivalent to a large excess, and preferably 1-3 equivalents, with respect to compound (d-19).
  • the reaction temperature is not particularly restricted but will normally be from room temperature to the reflux temperature of the solvent. Using a Dean-Stark trap can often produce favorable results such as increased yield.
  • Step D-15 is a step in which methyl of compound (d-20) is eliminated to obtain compound (d-21).
  • reaction in this step may be carried out under the same conditions as [Step D-12] described above.
  • Step D-16 is a step in which the double bond of compound (d-20) is reduced to obtain compound (d-22).
  • reaction in this step may be carried out under the same conditions as [Step D-11] described above.
  • Step D-17 is a step in which methyl of compound (d-22) is eliminated to obtain compound (d-23).
  • reaction in this step may be carried out under the same conditions as [Step D-12] described above.
  • Step D-18 is a step in which compound (d-24) and compound (d-25) are reacted in the presence of a base to obtain compound (d-26).
  • reaction in this step may be carried out under the same conditions as [Step B-7] described for [Production Process B] above.
  • Step D-19 is a step in which methyl of compound (d-26) is eliminated to obtain compound (d-27).
  • reaction in this step may be carried out under the same conditions as [Step D-12] described above.
  • Step D-20 is a step in which amino of compound (d-27) is protected with tert-butoxycarbonyl to obtain compound (d-28).
  • reaction may be carried out under the same conditions as commonly employed for tert-butoxycarbonylation of amino compounds (for example, the conditions described in T. W. Green and P. G. M. Wuts, “Protective Groups in Organic Synthesis, Third Edition”, John Wiley & Sons (1999), p. 518-525).
  • the reaction may be conducted by reaction with di-tert-butyl carbonate in an organic solvent, or in a mixture of water and an organic solvent, in the presence of a base.
  • the solvent used for the reaction may be diethyl ether, tetrahydrofuran, 1,4-dioxane, acetone, dichloromethane, chloroform, acetonitrile or the like, and the base used may be triethylamine or diisopropylethylamine.
  • a sodium hydroxide aqueous solution may also be used as the base.
  • Step D-21 is a step in which compound (d-28) and compound (b-2) are reacted to obtain compound (d-29).
  • the reaction in this step may be carried out under the same conditions as [Step B-2] described for [Production Process B] above.
  • Step D-22 is a step in which tert-butoxycarbonyl of compound (d-29) is eliminated to obtain compound (d-30).
  • reaction of this step may be carried out under the same conditions as in [Step D-2] described above, where Z 6 is tert-butoxycarbonyl.
  • Step D-23 is a step in which carbonyl of compound (d-30) is reduced to obtain compound (d-31).
  • the reduction reaction in this step is not particularly restricted, and it may be carried out under the same conditions as commonly employed for reduction of amide compounds to amines (for example, the conditions described in J. K. Thottathil, J. L. Moniot, R. H. Mueller, M. K. Y. Wong, and T. P. Kissick, J. Org. Chem., 51, 3140 (1986)).
  • the reducing agent used for the reaction in this step may be a metal hydride, and for example, lithium aluminum hydride or sodium bis(2-methoxyethoxy)aluminum hydride may be used.
  • the solvent used for the reaction in this step is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as examples there may be mentioned diethyl ether, tetrahydrofuran, 1,4-dioxane, toluene and the like.
  • the reaction temperature for this step will normally be from ice-cold to the reflux temperature of the solvent.
  • Step D-24 is a step in which compound (d-32) and compound (d-33) are subjected to nucleophilic substitution reaction to obtain compound (d-34).
  • reaction in this step may be carried out under the same conditions as [Step A-5] described for [Production Process A] above.
  • Compound (d-1) used in [Step D-1] and [Step D-6] for [Production Process D] described above may be synthesized in the following manner, for example.
  • Step D-25 is a step in which compound (d-35) and compound (d-36) are reacted to obtain compound (d-1a).
  • This step may be carried out under the same conditions as described in, for example, T. Mall and H. Stamm, Journal of Organic Chemistry, 52, 4812 (1987).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and when Z 1 is methyl, for example, methanol or N,N-dimethylformamide may be used.
  • the reaction temperature is not particularly restricted but will normally be from room temperature to the reflux temperature of the solvent.
  • Step D-26 is a step in which compound (d-37) and trifluoromethyltrimethylsilane are reacted in the presence of tetra-n-butylammonium fluoride to obtain compound (d-1b).
  • This step may be carried out under the same conditions as described in, for example, R. Krishnamurti, D. R. Bellew, and G. K. Surya Prakash, Journal of Organic Chemistry, 56, 984 (1991).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and tetrahydrofuran or the like may be used.
  • the reaction may also be carried out with a catalytic amount of tetra-n-butylammonium fluoride.
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to room temperature.
  • Step D-27 is a step in which compound (d-40) is obtained from compound (d-38).
  • compound (d-40) may be produced by reacting compound (d-38) with an organometallic reagent to form an anion, which is then reacted with a formic acid derivative.
  • lithium reagents such as n-butyllithium, sec-butyllithium, tert-butyllithium and phenyllithium are preferred.
  • N,N-dimethylformamide, N-formylpiperidine, N-formylmorpholine and N-methyl-N-phenylformamide are preferred.
  • the reaction temperature is not particularly restricted but is normally from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ⁇ 78° C. to room temperature.
  • the solvent used for the reaction is not particularly restricted so long as it does not inhibit the reaction, and may be diethyl ether, tetrahydrofuran or the like.
  • Step D-28 is a step in which carbonyl of compound (d-40) is reduced to obtain compound (d-41).
  • the reaction in this step may be carried out under the same conditions as [Step D-13] described above.
  • Step D-29 is a step in which hydroxyl of compound (d-41) is converted to a leaving group such as chlorine to obtain compound (d-42).
  • halogen chlorine, bromine, iodine
  • sulfonyloxy such as methanesulfonyloxy, p-toluenesulfonyloxy and trifluoromethanesulfonyloxy.
  • reaction may be carried out under the same conditions as commonly employed for reaction to convert hydroxyl to leaving groups (for example, the conditions described in R. K. Crossland and K. L. Servis, Journal of Organic Chemistry, 35, 3195 (1970)).
  • compound (d-41) when the leaving group is halogen, compound (d-41) may be produced by reaction with thionyl chloride, thionyl bromide, phosphorus tribromide or a tetrahalogenomethane-triphenylphosphine.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but benzene, toluene, xylene, dichloromethane and chloroform are preferred.
  • Favorable results in the reaction such as increased yield, can be obtained by addition of a base.
  • the base used is not particularly restricted so long as it does not inhibit the reaction, but sodium carbonate, potassium carbonate, triethylamine, pyridine and diisopropylethylamine are preferred.
  • the reaction temperature will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ice-cold to the reflux temperature of the solvent.
  • compound (d-41) may be produced by reaction with methanesulfonyl chloride, p-toluenesulfonyl chloride, trifluoromethanesulfonic anhydride or the like.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and there may be mentioned as preferable tetrahydrofuran, toluene, xylene, dichloromethane, chloroform and N,N-dimethylformamide
  • the reaction temperature will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ice-cold to room temperature.
  • the base used is not particularly restricted so long as it does not inhibit the reaction, but sodium carbonate, potassium carbonate, triethylamine, pyridine and diisopropylethylamine are preferred.
  • L x6 represents a chlorine or methanesulfonyloxy group.
  • Step D-30 is a step in which compound (d-43) and compound (d-44) are subjected to nucleophilic substitution reaction to obtain compound (d-45).
  • compound (d-44) may be reacted with a base to form an anion, which is then reacted with compound (d-43) to obtain compound (d-45).
  • Compound (d-44) will normally be used at 1-5 equivalents with respect to compound (d-43).
  • the solvent for the reaction is not particularly restricted so long as it does not inhibit the reaction, and a suitable base may be reacted at 1 equivalent to an excess, in an organic solvent such as diethyl ether, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, dimethyl sulfoxide, methanol or ethanol.
  • a suitable base there may be mentioned sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium methoxide, sodium ethoxide, potassium tert-butoxide, sodium carbonate, potassium carbonate, cesium carbonate and the like.
  • the reaction temperature is not particularly restricted but will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ice-cold to 100° C.
  • Step D-31 is a step in which methyl in compound (d-45) is eliminated to obtain compound (d-46).
  • reaction in this step may be carried out under the same conditions as [Step D-12] described above.
  • the starting materials used for [Production Process E] may be commercially available materials, or they may be produced by methods known to those skilled in the art from commercially available materials.
  • Step E-1 is a step in which compound (e-1) is reacted with ethyl carbazate to obtain compound (e-2).
  • reaction may be carried out under the same conditions as described in, for example, M. Pesson, S. Dupin, et M. Antoine, Bulletin de la Societe Chimic de France, 1364 (1962) and Resat UN and Aysun IKIZLER, Chimica Acta Turcica, 3, 113 (1975).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but methanol and ethanol are preferred.
  • Favorable results in the reaction, such as increased yield, can be obtained by addition of a base.
  • the base is not particularly restricted so long as it does not inhibit the reaction, and sodium methoxide or sodium ethoxide may be mentioned.
  • the reaction temperature will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ice-cold to the reflux temperature of the solvent.
  • Step E-2 is a step in which compound (e-2) and compound (e-3) are reacted to obtain compound (e-4).
  • reaction may be carried out under the same conditions as described in, for example, M. Pesson, S. Dupin, et M. Antoine, Bulletin de la Societe Chimic de France, 1364 (1962) and Resat UN and Aysun IKIZLER, Chimica Acta Turcica, 3, 113 (1975).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but methanol, ethanol, propanol, acetonitrile and N,N-dimethylformamide are preferred.
  • Favorable results in the reaction can be obtained by addition of a base.
  • the base is not particularly restricted so long as it does not inhibit the reaction, and sodium methoxide or sodium ethoxide may be mentioned.
  • the reaction temperature will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from room temperature to the reflux temperature of the solvent.
  • Step E-3 is a step in which compound (e-5) and compound (e-6) are reacted to obtain compound (e-4).
  • reaction may be carried out under the same conditions as described in, for example, M. Pesson, S. Dupin, et M. Antoine, Bulletin de la Societe Chimic de France, 1364 (1962) and Resat UN and Aysun IKIZLER, Chimica Acta Turcica, 3, 113 (1975).
  • compound (e-5) and compound (e-6) are reacted, and the obtained compound is subjected to ring closure reaction in the presence of a base to obtain compound (e-4).
  • the solvent used for the reaction between compound (e-5) and compound (e-6) is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but methanol, ethanol and N,N-dimethylformamide are preferred.
  • the reaction temperature will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from room temperature to the reflux temperature of the solvent.
  • the solvent used for the ring closure reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but aqueous sodium hydroxide and aqueous potassium hydroxide are preferred.
  • the reaction temperature will normally be from room temperature to the reflux temperature of the solvent.
  • Step E-4 is a step in which amino of compound (e-2) is carbamoylated to obtain compound (e-8).
  • reaction may be carried out under the same conditions as described in H. R. Kricheidorf, Justus Liebig's Annalen der Chemie, 1816 (1973), for example.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and there may be mentioned as preferable acetonitrile, tetrahydrofuran, toluene, xylene, dichloromethane, chloroform, N,N-dimethylformamide and pyridine.
  • the reaction temperature will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ice-cold to room temperature.
  • the reaction is preferably carried out in the presence of a base.
  • the base used is not particularly restricted so long as it does not inhibit the reaction, but sodium carbonate, potassium carbonate, triethylamine, pyridine and diisopropylethylamine are preferred.
  • Step E-5 is a step in which compound (e-8) and hydrazine are reacted to obtain compound (e-9).
  • the reaction may be carried out under the same conditions as described in, for example, Q. Sun, L. Tafesse, K. Islam, X. Zhou, S. F. Victory, C. Zhongwu, M. Hachicha, L. A. Schmid, A. Patel, Y. Rotshteyn, K. J. Valenzano and D. J. Kyle, Bioorganic & Medicinal Chemistry Letters, 13, 3611 (2003).
  • the hydrazine used for the reaction may be a hydrate or anhydrous.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but methanol, ethanol and propanol are preferred.
  • the reaction temperature will normally be from ice-cold to the reflux temperature of the solvent.
  • Step E-6 is a step in which compound (e-9) and methyl orthoacetate are reacted to obtain compound (e-10).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but methanol, ethanol and propanol are preferred.
  • the reaction temperature will normally be from ice-cold to the reflux temperature of the solvent.
  • Step E-7 is a step in which compound (e-2) and oxalyl chloride are reacted to obtain compound (e-11).
  • the reaction may be carried out under the same conditions commonly employed for production of isocyanates from amines (for example, the conditions described in A. J. Speziale, L. R. Smith, Organic Synthesis, 46, 16 (1966)).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but dichloromethane, chloroform and 1,2-dichloroethane are preferred.
  • the reaction temperature will normally be from ice-cold to the reflux temperature of the solvent.
  • Step E-8 is a step in which compound (e-11) is reacted with tert-butyl carbazate to obtain compound (e-12).
  • the reaction may be conducted under the same conditions as commonly employed for production of ureas from isocyanates (for example, the conditions described in J. K. Snyder and L. M. Stock, Journal of Organic Chemistry, 45, 886 (1980)).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, toluene, xylene and ethyl acetate are preferred.
  • the reaction temperature will normally be from ice-cold to the reflux temperature of the solvent.
  • Step E-9 is a step in which tert-butoxycarbonyl of compound (e-12) is deprotected to obtain compound (e-9).
  • reaction may be carried out under the same conditions as commonly employed for deprotection of tert-butoxycarbonyl (for example, the conditions described in T. W. Green and P. G. M. Wuts, “Protective Groups in Organic Synthesis, Third Edition”, John Wiley & Sons (1999), p. 518-525).
  • the solvent for the reaction is not particularly restricted so long as it does not inhibit the reaction, and the reaction may be conducted with a suitable acid such as hydrogen chloride, hydrochloric acid, sulfuric acid, trifluoroacetic acid or p-toluenesulfonic acid in an organic solvent such as diethyl ether, tetrahydrofuran, 1,4-dioxane, acetone or ethyl acetate, or in a mixture of water and an organic solvent.
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to the reflux temperature of the solvent, and is preferably from ice-cold to room temperature.
  • Step E-10 is a step in which compound (e-13) and compound (e-14) are reacted to obtain compound (e-15).
  • reaction in this step may be carried out under the same conditions as [Step E-8] described above.
  • Step E-11 is a step in which compound (e-15) is subjected to ring closure reaction under basic conditions to obtain compound (e-16).
  • the solvent used for the ring closure reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but aqueous sodium hydroxide and aqueous potassium hydroxide are preferred.
  • the reaction temperature will normally be from room temperature to the reflux temperature of the solvent.
  • Step E-12 is a step in which compound (e-13) and trichloromethyl chloroformate are reacted to obtain compound (e-17).
  • reaction may be carried out under the same conditions as described in the literature, such as F. Chau, J-C. Maieria and R. Milcent, Journal of Heterocyclic Chemistry, 34, 1603 (1997), EP321833, for example.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, toluene, xylene and ethyl acetate are preferred.
  • the reaction temperature will normally be from ice-cold to the reflux temperature of the solvent.
  • Step E-13 is a step in which compound (e-17) and compound (e-18) are reacted to obtain compound (e-16).
  • the reaction in this step may be carried out under the same conditions as [Step E-3] described above.
  • Step E-14 is a step in which compound (e-19) and hydrazine are reacted to obtain compound (e-20).
  • reaction in this step may be carried out under the same conditions as [Step E-5] described above.
  • the product may be used directly for the following step without purification.
  • Step E-15 is a step in which the amino group of compound (e-20) is carbamoylated to obtain compound (e-21).
  • reaction in this step may be carried out under the same conditions as [Step E-4] described above.
  • the product may be used directly for the following step without purification.
  • Step E-16 is a step in which compound (e-21) is subjected to ring closure reaction to obtain compound (e-22).
  • compound (e-21) may be dissolved in a solvent and heated to obtain compound (e-22).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but toluene, xylene and N,N-dimethylformamide are preferred.
  • the reaction temperature will normally be from room temperature to the reflux temperature of the solvent.
  • Step E-17 is a step in which the amino group of compound (e-23) is carbamoylated to obtain compound (e-24).
  • the reaction in this step may be carried out under the same conditions as [Step E-4] described above.
  • Step E-18 is a step in which compound (e-24) is subjected to ring closure reaction to obtain compound (e-25).
  • reaction in this step may be carried out under the same conditions as [Step E-16] described above.
  • Step E-19 is a step in which compound (e-26) is reacted with ethyl carbazate to obtain compound (e-27).
  • reaction in this step may be carried out under the same conditions as [Step E-14] described above.
  • Step E-20 is a step in which compound (e-27) is subjected to ring closure reaction to obtain compound (e-28).
  • reaction in this step may be carried out under the same conditions as [Step E-16] described above.
  • the starting materials used for [Production Process F] may be commercially available materials, or they may be produced by methods known to those skilled in the art from commercially available materials.
  • Step F-1 is a step in which the carbonyl group of compound (f-1) is thiocarbonylated to obtain compound (f-2).
  • the reaction may be carried out under the same conditions as commonly employed for thiocarbonylation of carbonyl (for example the conditions described in M. P. Cava and M. I. Levinson, Tetrahedron, 41, 5061 (1985)).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, toluene, xylene and pyridine are preferred.
  • the reaction temperature will normally be from room temperature to the reflux temperature of the solvent.
  • Step F-2 is a step in which compound (f-2) is reacted with silver cyanate to obtain compound (f-3).
  • reaction may be carried out under the same conditions as described in the literature, such as I. Shibuya, K. Honda, Y. Gama, M Shimizu, Heterocycles, 53, 929 (2000), for example.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but acetonitrile and propionitrile are preferred.
  • the reaction is preferably carried out in the presence of a base.
  • the base used is not particularly restricted so long as it does not inhibit the reaction, and there may be mentioned triethylamine and diisopropylethylamine.
  • the reaction temperature will normally be from room temperature to the reflux temperature of the solvent.
  • Step F-3 is a step in which compound (f-4) and compound (f-5) are reacted to obtain compound (f-6).
  • the reaction may be carried out under the same conditions as commonly employed for production of amidines from imidates (for example, the conditions described in A. W. Dox, Organic Synthesis, I, 5 (1941)).
  • Compound (f-5) used for the reaction may be a salt or in free form.
  • Preferable salt is hydrochloride.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but methanol, ethanol and propanol are preferred.
  • Favorable results in the reaction, such as increased yield, can be obtained by addition of a base.
  • the base used is not particularly restricted so long as it does not inhibit the reaction, and triethylamine and diisopropylethylamine may be mentioned.
  • the reaction temperature will normally be from ice-cold to the reflux temperature of the solvent.
  • Step F-4 is a step in which compound (f-6) and compound (c-1) or phenoxycarbonyl isocyanate are reacted to obtain compound (f-3).
  • reaction in this step may be carried out under the same conditions as [Step C-1] described for [Production Process C] above in the case of reacting compound (f-6) with compound (c-1).
  • the reaction in this step may be carried out under the same conditions as described in the literatures such as P. Rao and S. A. Benner, Journal of Organic Chemistry, 66, 5012 (2001), Y. Watanabe, H. Usui, S. Kobayashi, H. Yoshizawa, T. Shibano, T. Tanaka, Y. Morishita, M. Yasuoka and M. Kanao, Journal of Medicinal Chemistry, 35, 189 (1992) in the case of reacting compound (f-6) with phenoxycarbonyl isocyanate.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and there may be mentioned tetrahydrofuran, benzene, toluene, xylene, acetonitrile, dichloromethane, chloroform, N,N-dimethylformamide and dimethylsulfoxide.
  • the reaction temperature will normally be from ice-cold to the reflux temperature of the solvent, and preferably from room temperature to the reflux temperature of the solvent.
  • Step F-5 is a step in which compound (f-7) and compound (c-1) or phenoxycarbonyl isocyanate are reacted to obtain compound (f-8).
  • the reaction in this step may be carried out under the same conditions as [Step F-4].
  • Step F-6 is a step in which compound (f-9) and phenoxycarbonyl isocyanate are reacted to obtain compound (f-10).
  • the reaction in this step may be carried out under the same conditions as described in the literatures such as P. Rao and S. A. Benner, Journal of Organic Chemistry, 66, 5012 (2001), Y. Watanabe, H. Usui, S. Kobayashi, H. Yoshizawa, T. Shibano, T. Tanaka, Y. Morishita, M. Yasuoka and M. Kanao, Journal of Medicinal Chemistry, 35, 189 (1992).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and there may be mentioned tetrahydrofuran, benzene, toluene, xylene, acetonitrile, dichloromethane, chloroform, N,N-dimethylformamide and dimethylsulfoxide.
  • the reaction temperature will normally be from ice-cold to the reflux temperature of the solvent, and preferably from room temperature to the reflux temperature of the solvent.
  • Step F-7 is a step in which compound (f-11) and compound (c-1) are reacted to obtain compound (f-12).
  • reaction in this step may be carried out under the same conditions as [Step C-2] described for [Production Process C] above.
  • Step F-8 is a step in which compound (f-13) and compound (c-1) are reacted to obtain compound (f-14).
  • reaction in this step may be carried out under the same conditions as [Step C-2] described for [Production Process C] above.
  • Step F-9 is a step in which compound (f-15) and compound (f-16) are reacted to obtain compound (f-17).
  • reaction in this step may be carried out under the same conditions as [Step C-2] described for [Production Process C] above.
  • the starting materials used for [Production Process G] may be commercially available materials, or they may be produced by methods known to those skilled in the art from commercially available materials.
  • Step G-1 is a step in which compound (g-1) is reacted with compound (g-2) or trifluoromethanesulfonic anhydride to convert hydroxyl to a leaving group and obtain compound (g-3).
  • the reaction may be carried out under the same conditions as commonly employed for conversion of hydroxyl to leaving groups such as p-toluenesulfonyloxy (for example, the conditions described in Y. Yoshida, Y. Sakakura, N. Aso, S. Okada, and Y. Tanabe, Tetrahedron, 55, 2183 (1999)).
  • leaving groups such as p-toluenesulfonyloxy
  • compound (g-1) may be reacted with methanesulfonyl chloride, p-toluenesulfonyl chloride, p-nitrobenzenesulfonyl chloride or the like to produce compound (g-3).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as specific examples there may be mentioned dichloromethane, chloroform, tetrahydrofuran, toluene, xylene, acetonitrile and N,N-dimethylformamide
  • the reaction temperature will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ⁇ 78° C. to room temperature.
  • the reaction is preferably carried out in the presence of a base.
  • the base used is not particularly restricted so long as it does not inhibit the reaction, and as preferred examples there may be mentioned sodium carbonate, potassium carbonate, triethylamine, diisopropylethylamine and pyridine. Preferred results such as increased yield may be obtained if the reaction is conducted in the presence of trimethylammonium chloride.
  • reaction may also be carried out under the same conditions as commonly employed for conversion of hydroxyl to leaving groups such as trifluoromethanesulfonyloxy (for example, P. J. Stang, M. Hanack, L. R. Subramanian, Synthesis, 85 (1982)).
  • leaving groups such as trifluoromethanesulfonyloxy (for example, P. J. Stang, M. Hanack, L. R. Subramanian, Synthesis, 85 (1982)).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as preferred examples there may be mentioned dichloromethane, chloroform, tetrahydrofuran and pyridine.
  • the reaction temperature will normally be from ⁇ 78° C. to the reflux temperature of the solvent, and is preferably from ice-cold to room temperature.
  • the reaction is preferably carried out in the presence of a base.
  • the base used is not particularly restricted so long as it does not inhibit the reaction, but pyridine and 2,6-lutidine are preferred.
  • Step G-2 is a step in which the hydroxyl of compound (g-4) is protected with trityl to obtain compound (g-5).
  • reaction may be carried out under the same conditions as commonly employed for protection of hydroxyl with trityl groups (for example, the conditions described in T. W. Green and P. G. M. Wuts, “Protective Groups in Organic Synthesis, Third Edition”, John Wiley & Sons (1999), p. 102-104).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as preferred examples there may be mentioned dichloromethane, chloroform, tetrahydrofuran, pyridine, toluene, xylene, N,N-dimethylformamide and pyridine.
  • the reaction is preferably carried out in the presence of a base.
  • the base used is not particularly restricted so long as it does not inhibit the reaction, but triethylamine, diisopropylethylamine, pyridine and 2,6-lutidine are preferred.
  • DMAP 4-dimethylaminopyridine
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to the reflux temperature of the solvent.
  • Step G-3 is a step in which the hydroxyl of compound (g-5) is fluorinated to obtain compound (g-6).
  • the fluorinating agent is preferably perfluoro-1-butanesulfonyl fluoride.
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, but toluene and xylene are preferred.
  • the reaction is preferably carried out in the presence of a base.
  • the base used is not particularly restricted so long as it does not inhibit the reaction, but 1,8-diazabicyclo[5.4.0]-7-undecene is preferred.
  • Step G-4 is a step in which trityl of compound (g-6) is deprotected to obtain compound (g-7).
  • reaction may be carried out under the same conditions as commonly employed for deprotection of trityl (for example, the conditions described in T. W. Green and P. G. M. Wuts, “Protective Groups in Organic Synthesis, Third Edition”, John Wiley & Sons (1999), p. 102-104).
  • the solvent used for the reaction is not particularly restricted so long as it does not inhibit the reaction, and an appropriate acid such as acetic acid, hydrogen chloride, hydrochloric acid, sulfuric acid, trifluoroacetic acid or p-toluenesulfonic acid may be reacted in an organic solvent such as diethyl ether, tetrahydrofuran, 1,4-dioxane, acetone or ethyl acetate, or in a mixture of water and an organic solvent. Hydrous acetic acid may also be used as the solvent.
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to the reflux temperature of the solvent.
  • Step G-5 is a step in which compound (g-7) is reacted with compound (g-8) to protect hydroxyl and obtain compound (g-9).
  • reaction may be carried out under the same conditions as commonly employed for protection of hydroxyl with silyl (for example, the conditions described in T. W. Green and P. G. M. Wuts, “Protective Groups in Organic Synthesis, Third Edition”, John Wiley & Sons (1999), p. 113-148).
  • the solvent used for the reaction is not particularly restricted so long as it dissolves the starting materials to some extent without inhibiting the reaction, and as preferred examples there may be mentioned dichloromethane, chloroform, tetrahydrofuran, pyridine, toluene, xylene, N,N-dimethylformamide and pyridine.
  • the reaction is preferably carried out in the presence of a base.
  • the base used is not particularly restricted so long as it does not inhibit the reaction, but imidazole and pyridine are preferred.
  • the reaction temperature is not particularly restricted but will normally be from ice-cold to room temperature.
  • Step G-6 is a step in which the benzyl group of compound (g-9) is deprotected to obtain compound (g-10).
  • reaction in this step may be carried out under the same conditions as [Step C-4] described for [Production Process C] above.
  • Step G-7 is a step in which compound (g-10) is reacted with compound (g-2) or trifluoromethanesulfonic anhydride to convert the hydroxyl to a leaving group and obtain compound (g-12).
  • the reaction in this step may be carried out under the same conditions as [Step G-1] described above.
  • Various isomers for example, geometric isomers, or optical isomers based on asymmetric carbons, rotational isomers, stereoisomers and the like
  • compound (I) of the invention may be purified and isolated using ordinary separation means such as, for example, recrystallization, a diastereomer salt method, enzymatic resolution or chromatography methods (for example, thin-layer chromatography, column chromatography, gas chromatography, etc.).
  • the compounds of the invention and salts thereof, as well as hydrates of the foregoing, can therefore be used to obtain pharmaceutical compositions as therapeutic agents and analgesics for diseases for which sodium channel inhibition is effective, such as various kinds of neuralgia (for example, diabetic neuralgia, HIV-induced neuralgia, postherpetic neuralgia, trigeminal neuralgia, stump pain, post-spinal cord injury pain, thalamic pain and post-apoplectic pain), epilepsy, insomnia, premature ejaculation and the like.
  • neuralgia for example, diabetic neuralgia, HIV-induced neuralgia, postherpetic neuralgia, trigeminal neuralgia, stump pain, post-spinal cord injury pain, thalamic pain and post-apoplectic pain
  • epilepsy for example, epilepsy, insomnia, premature ejaculation and the like.
  • administration of pharmacologically effective doses of compounds of the invention and salts thereof, or hydrates of the foregoing, to patients with disease for which sodium channel inhibition is effective or with neuralgia can serve as treatment for diseases for which sodium channel inhibition is effective or with neuralgia.
  • the compounds of the invention and salts thereof, or hydrates of the foregoing may be formulated into tablets, powders, fine granules, granules, coated tablets, capsules, syrups, lozenges, inhalants, suppositories, injections, ointments, eye salves, eye drops, nose drops, ear drops, poultices, lotions and the like by ordinary methods.
  • excipients there may also be used excipients, binders, lubricants, coloring agents, taste correctives and the like ordinarily used for formulation, as well as stabilizers, emulsifiers, absorption accelerators, surfactants, pH regulators, antiseptic agents and antioxidants as necessary, for formulation by ordinary methods using components commonly used as starting materials for drugs.
  • animal and vegetable oils such as soybean oil, beef tallow and synthetic glycerides
  • hydrocarbons such as liquid paraffins, squalane and solid paraffins
  • ester oils such as octyldodecyl myristate and isopropyl myristate
  • higher alcohols such as cetostearyl alcohol and behenyl alcohol
  • silicon resins silicon oils
  • surfactants such as polyoxyethylene fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, polyoxyethylenesorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil and polyoxyethylene-polyoxypropylene block copolymer
  • water-soluble polymers such as hydroxyethylcellulose, polyacrylic acid, carboxyvinyl polymer, polyethylene glycol, polyvinylpyrrolidone and methylcellulose
  • lower alcohols such as ethanol and isopropanol
  • polyhydric alcohols such as glycerin, propy
  • excipients include lactose, corn starch, white soft sugar, glucose, mannitol, sorbitol, crystalline cellulose, silicon dioxide and the like
  • examples of binders include polyvinyl alcohol, polyvinyl ether, methylcellulose, ethylcellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polypropylene glycol-polyoxyethylene block copolymer, meglumine and the like
  • examples of disintegrators include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium hydrogencarbonate, calcium citrate, dextrin, pectin, carboxymethylcellulose calcium and the like
  • examples of lubricants include magnesium stearate, talc, polyethylene glycol, silica, hydrogenated vegetable oils and the like
  • examples of coloring agents include those approved for addition to drugs
  • examples of taste correctives include cocoa powder,
  • a compound of the invention or its pharmacologically acceptable salt may be combined with an excipient, and with a binder, disintegrator, lubricant, coloring agent or taste corrective as necessary, to form a powder, fine granules, granules, tablets, coated tablets, capsules or the like.
  • Such tablets or granules may of course be provided with a sugar coating or other appropriate coating as necessary.
  • a pH regulator, solubilizer, isotonizing agent or the like, and if necessary also a dissolving aid or stabilizer may be added to the compound of the invention or its pharmacologically acceptable salt, for formulation by an ordinary method.
  • the starting materials used for formulation may be any of various commonly employed starting materials for drugs, quasi drugs, cosmetics and the like.
  • specific starting materials to be used there may be mentioned animal and vegetable oils, mineral oils, ester oils, waxes, higher alcohols, fatty acids, silicon oils, surfactants, phospholipids, alcohols, polyhydric alcohols, water-soluble polymers, clay minerals, purified water and the like, while pH regulators, antioxidants, chelating agents, antiseptic and fungicides, coloring agents, aromatics and the like may also be added; however, the base starting materials for an external preparation of the invention are not limited to these.
  • additional components such as blood flow accelerators, microbicides, antiphlogistics, cellular stimulants, vitamins, amino acids, humectants, keratolytic drugs and the like may also be added.
  • the amounts of such base starting materials added may be such as to give concentrations ordinarily established for production of external preparations.
  • a compound of the invention or salt thereof, or a solvate of the foregoing when administered, it may be in any desired form without restrictions, such as an oral administration or parenteral administration, according to a commonly employed procedure.
  • it may be formulated for administration in the form of tablets, powders, granules, capsules, syrups, lozenges, inhalants, suppositories, injections, ointments, eye salves, eye drops, nose drops, ear drops, poultices, lotions or the like.
  • the dosage for administration of a drug according to the invention may be appropriately selected according to the age, gender, body weight and degree of symptoms of the patient, and the specific type of condition and the form of administration, type of salt, etc.
  • the dosage for administration of a drug according to the invention will differ depending on the patient's condition, severity of symptoms, age, gender and sensitivity to drugs, but for adults it will normally be about 0.03-1000 mg and preferably 0.1-500 mg per day for oral administration, and about 1-3000 ⁇ g/kg body weight and preferably about 3-1000 ⁇ g/kg body weight for injection, administered either at once or in divided doses.
  • the compounds according to the invention may be produced by the methods described by the following production examples and examples. However, these specific examples are merely illustrative and the compounds of the invention are in no way restricted by these concrete examples.
  • Tropine (25.0 g) was dissolved in 1-methyl-2-pyrrolidinone (350 ml), and then sodium hydride (60% in oil) (9.2 g) was added and the mixture was stirred at 75° C. for 2 hours.
  • the reaction mixture was cooled on ice, 4-fluorobenzyl bromide (26.5 ml) was added and the mixture was stirred at room temperature for 69 hours. Ice water was added to the reaction mixture and extraction was performed with n-heptane. The organic layer was washed with water and brine in that order and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain the title compound (36.76 g).
  • the title compound (21.34 g) was obtained from tropine (15.0 g) and 3-fluorobenzyl bromide by the method similar to Production Example 1-(1).
  • the title compound (12.74 g) was obtained from tropine (10.0 g) and 2-methylbenzyl bromide by the method similar to Production Example 1-(1).
  • the title compound (8.4 g) was obtained from the compound obtained in Production Example 3-(1) (12.74 g) by the method similar to Production Example 1-(2).
  • the title compound (4.68 g) was obtained from tropine (5.0 g) and benzyl bromide by the method similar to Production Example 1-(1).
  • the title compound (2.98 g) was obtained from the compound obtained in Production Example 4-(1) (4.68 g) by the method similar to Production Example 1-(2).
  • the title compound (17.29 g) was obtained from tropine (15.0 g) and 2-fluorobenzyl bromide by the method similar to Production Example 1-(1).
  • the title compound (1.7 g) was obtained from tropine (4.0 g) and 2-chloromethyl-benzo[b]thiophene (CAS 2076-88-2) by the method similar to Production Example 1-(1).
  • the title compound (4.2 g) was obtained from tropine (3.5 g) and 3-chloromethyl-benzo[b]thiophene (CAS 3216-47-5) by the method similar to Production Example 1-(1).
  • the title compound (7.06 g) was obtained from tropine (5.0 g) and 2-chloromethyl-thiophene (CAS 765-50-4) by the method similar to Production Example 1-(1).
  • the title compound (880 mg) was obtained from the compound obtained in Production Example 8-(1) (7.06 g) by the method similar to Production Example 5-(2).
  • Tropine (3.0 g) was dissolved in 1-methyl-2-pyrrolidinone (40 ml), and then sodium hydride (60% in oil) (1.19 g) was added and the mixture was stirred at 75° C. for 2 hours.
  • the reaction mixture was cooled on ice, and then a solution of benzyltri-n-butylammonium bromide (377 mg) and 2-methoxymethylbenzyl chloride (CAS 68718-99-0) (4.64 g) in 1-methyl-2-pyrrolidinone (5 ml) was added dropwise and the mixture was stirred at room temperature for 22 hours. Water was added to the reaction mixture, and extraction was performed with ethyl acetate.
  • the title compound (2.01 g) was obtained from the compound obtained in Production Example 9-(1) (3.95 g) by the method similar to Production Example 5-(2).
  • the title compound (3.95 g) was obtained from tropine (3.0 g) and 2-methoxybenzyl chloride by the method similar to Production Example 9-(1).
  • the title compound (2.71 g) was obtained from the compound obtained in Production Example 10-(1) (3.95 g) by the method similar to Production Example 5-(2).
  • Tropine (5.0 g) was dissolved in 1-methyl-2-pyrrolidinone (70 ml), and then sodium hydride (60% in oil) (1.98 g) was added and the mixture was stirred at 75° C. for 45 minutes. The reaction mixture was allowed to cool, and bromomethylcyclohexane (5.93 ml) was added dropwise. After stirring at room temperature for 13 hours, water was added to the reaction mixture and extraction was performed with ethyl acetate. The organic layer was washed with water and brine in that order and then dried over anhydrous magnesium sulfate. After filtration, the solvent was distilled off under reduced pressure. The residue was purified by NH silica gel column chromatography to obtain the title compound (528 mg).
  • the title compound (297 mg) was obtained from the compound obtained in Production Example 11-(1) (528 mg) by the method similar to Production Example 5-(2).
  • the title compound (1.5 g) was obtained from tropine (3.0 g) and 2-trifluoromethoxybenzyl bromide by the method similar to Production Example 11-(1).
  • the title compound (2.65 g) was obtained from tropine (3.0 g) and 2-trifluoromethylbenzyl bromide by the method similar to Production Example 11-(1).
  • the title compound (2.65 g) was obtained from tropine (5.0 g) and 3,4-difluoromethylbenzyl bromide by the method similar to Production Example 11-(1).
  • the title compound (2.69 g) was obtained from the compound obtained in Production Example 14-(1) (3.43 g) by the method similar to Production Example 5-(2).
  • the title compound was obtained from tropine (5.0 g) and 3-methoxybenzyl chloride by the method similar to Production Example 11-(1).
  • the title compound (3.38 g) was obtained from the compound obtained in Production Example 15-(1) by the method similar to Production Example 5-(2).
  • the reaction mixture was concentrated under reduced pressure, a 2N aqueous solution of sodium hydroxide (15 ml) and a solution of di-tert-butyl dicarbonate (1.9 g) in tetrahydrofuran (15 ml) were added to the residue, and the mixture was stirred at room temperature for 40 hours. Water was added to the reaction mixture, and extraction was performed with ethyl acetate. The organic layer was washed with water and brine in that order and then dried over anhydrous magnesium sulfate. After filtration, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (1.53 g).
  • the organic layer was washed with water, 1N hydrochloric acid, a saturated aqueous solution of sodium hydrogencarbonate and brine in that order, and dried over anhydrous magnesium sulfate. After filtration, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (2.70 g).
  • the title compound (3.32 g) was obtained from (endo)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (CAS 143557-91-9) (2.00 g) and 2,6-dimethylbenzyl chloride (CAS 5402-60-8) by the method similar to Production Example 19-(2).
  • the title compound (2.15 g) was obtained from the compound obtained in Production Example 20-(1) (3.32 g) by the method similar to Production Example 19-(3).
  • the title compound (1.65 g) was obtained from the compound obtained in Production Example 21-(1) (2.28 g) by the method similar to Production Example 19-(3).
  • the title compound (1.40 g) was obtained from the compound obtained in Production Example 22-(1) (2.05 g) by the method similar to Production Example 19-(3).
  • the title compound (344 mg) was obtained from the compound obtained in Production Example 23-(1) (511 mg) by the method similar to Production Example 19-(3).
  • the title compound (184 mg) was obtained from the compound obtained in Production Example 24-(1) (235 mg) by the method similar to Production Example 19-(3).
  • the title compound (2.52 g) was obtained from (endo)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (CAS 143557-91-9) (4.21 g) and the compound obtained in Production Example 25-(1), by the method similar to Production Example 19-(2).
  • the title compound (1.80 g) was obtained from the compound obtained in Production Example 25-(2) (2.52 g) by the method similar to Production Example 19-(3).
  • the title compound (6.38 g) was obtained from (endo)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (CAS 143557-91-9) (5.50 g) and 3-chloromethyl-thiophene (CAS 2746-23-8) by the method similar to Production Example 19-(2).
  • the title compound (1.03 g) was obtained from the compound obtained in Production Example 29-(1) (1.46 g) by the method similar to Production Example 28-(2).
  • the title compound (611 mg) was obtained from the compound obtained in Production Example 30-(1) (803 mg) by the method similar to Production Example 28-(2).
  • the title compound (500 mg) was obtained from the compound of Production Example 32-(1) (734 mg) by the method similar to Production Example 31-(2).
  • the title compound (1.26 g) was obtained from the compound obtained in Production Example 33-(1) (1.76 g) by the method similar to Production Example 19-(3).
  • the title compound (1.33 g) was obtained from (endo)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (CAS 143557-91-9) (1.00 g) and the compound obtained in Production Example 34-(3), by the method similar to Production Example 28-(1).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
US12/867,024 2008-02-13 2009-02-09 Bicycloamine derivatives Abandoned US20100331310A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/867,024 US20100331310A1 (en) 2008-02-13 2009-02-09 Bicycloamine derivatives

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2837808P 2008-02-13 2008-02-13
JP2008-031939 2008-02-13
JP2008031939 2008-02-13
PCT/JP2009/052164 WO2009101917A1 (fr) 2008-02-13 2009-02-09 Dérivé de bicycloamine
US12/867,024 US20100331310A1 (en) 2008-02-13 2009-02-09 Bicycloamine derivatives

Publications (1)

Publication Number Publication Date
US20100331310A1 true US20100331310A1 (en) 2010-12-30

Family

ID=40956948

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/867,024 Abandoned US20100331310A1 (en) 2008-02-13 2009-02-09 Bicycloamine derivatives
US12/368,069 Expired - Fee Related US8252810B2 (en) 2008-02-13 2009-02-09 Bicycloamine derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/368,069 Expired - Fee Related US8252810B2 (en) 2008-02-13 2009-02-09 Bicycloamine derivatives

Country Status (12)

Country Link
US (2) US20100331310A1 (fr)
EP (1) EP2241567A4 (fr)
JP (1) JPWO2009101917A1 (fr)
KR (1) KR20100124262A (fr)
CN (1) CN101910169A (fr)
AU (1) AU2009213488A1 (fr)
CA (1) CA2714591A1 (fr)
IL (1) IL206875A0 (fr)
MX (1) MX2010008818A (fr)
RU (1) RU2010137862A (fr)
WO (1) WO2009101917A1 (fr)
ZA (1) ZA201005769B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026378A1 (fr) * 2019-08-07 2021-02-11 Alkermes, Inc. Composés d'indole pour le traitement de la douleur
WO2021026377A1 (fr) * 2019-08-07 2021-02-11 Alkermes, Inc. Composés contenant du lactame pour le traitement de la douleur
WO2021026375A1 (fr) * 2019-08-07 2021-02-11 Alkermes, Inc. Composés bicycliques fusionnés pour le traitement de la douleur

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101584826B1 (ko) * 2008-02-20 2016-01-18 노파르티스 아게 스테아로일-ＣｏＡ 데새투라제의 헤테로시클릭 억제제
PL2399910T3 (pl) 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
BR112012033402A2 (pt) * 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
RU2565073C2 (ru) 2010-08-10 2015-10-20 Сионоги Энд Ко., Лтд. Триазиновое производное и включающая его фармацевтическая композиция, обладающая анальгетической активностью
US9212130B2 (en) 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
BR112013028886A2 (pt) 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
NO3175985T3 (fr) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
WO2013074386A2 (fr) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Inhibiteurs de la protéase ns3 du vhc
JP6124351B2 (ja) 2012-02-09 2017-05-10 塩野義製薬株式会社 複素環および炭素環誘導体
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
CN107349204A (zh) * 2017-07-11 2017-11-17 东新皓特（北京）生化科技有限公司 河豚毒素在制备治疗带状疱疹病症药物组合物中的应用、药物组合物及外用药
TW201945346A (zh) * 2018-04-10 2019-12-01 德商拜耳廠股份有限公司 2,4,5-三取代的1,2,4-三唑酮之製備方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220368A1 (en) * 2000-01-20 2003-11-27 Fumihiro Ozaki Novel piperidine compouds and drugs containing the same
US20050020654A1 (en) * 2003-03-15 2005-01-27 Pershadsingh Harrihar A. Novel PPAR agonists, pharmaceutical compositions and uses thereof
US20090131412A1 (en) * 2005-06-07 2009-05-21 Dainippon Sumitomo Pharma Co., Ltd. Novel 2-quinolone derivative

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827264A1 (de) 1987-12-22 1989-07-13 Bayer Ag Verfahren zur herstellung von 4-amino-1,2,4-triazol-5-onen
US6248889B1 (en) 1998-11-20 2001-06-19 3M Innovative Properties Company Process for converting an alcohol to the corresponding fluoride
US6432976B1 (en) * 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
ES2338539T3 (es) 2001-11-01 2010-05-10 Icagen, Inc. Pirazolamidas para uso en el tratamiento del dolor.
EP1506196B1 (fr) 2001-11-01 2012-01-18 Icagen, Inc. Pyrazolopyrimidines en tant que bloqueurs du canal sodium
CA2465328C (fr) 2001-11-01 2011-06-14 Michael Francis Gross Piperidines
RU2005129550A (ru) * 2003-02-27 2006-07-27 Ф.Хоффманн-Ля Рош Аг (Ch) Антагонисты рецептора ccr-3
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
ATE469897T1 (de) 2004-12-22 2010-06-15 Theravance Inc Indazolcarbonsäureamidverbindungen
GB0500300D0 (en) 2005-01-07 2005-02-16 Ionix Pharmaceuticals Ltd Chemical compositions
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
US7317022B2 (en) 2005-06-07 2008-01-08 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
NL2000284C2 (nl) 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
CA2633329A1 (fr) 2006-01-23 2007-07-26 Pfizer Limited Derives de pyridine en tant que modulateurs du canal sodium
WO2008016811A2 (fr) * 2006-07-31 2008-02-07 Neurogen Corporation Aminopipéridines et composés apparentés

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220368A1 (en) * 2000-01-20 2003-11-27 Fumihiro Ozaki Novel piperidine compouds and drugs containing the same
US6784192B2 (en) * 2000-01-20 2004-08-31 Eisai Co., Ltd. Piperidine compound and pharmaceutical composition thereof
US20050020654A1 (en) * 2003-03-15 2005-01-27 Pershadsingh Harrihar A. Novel PPAR agonists, pharmaceutical compositions and uses thereof
US20090131412A1 (en) * 2005-06-07 2009-05-21 Dainippon Sumitomo Pharma Co., Ltd. Novel 2-quinolone derivative

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026378A1 (fr) * 2019-08-07 2021-02-11 Alkermes, Inc. Composés d'indole pour le traitement de la douleur
WO2021026377A1 (fr) * 2019-08-07 2021-02-11 Alkermes, Inc. Composés contenant du lactame pour le traitement de la douleur
WO2021026375A1 (fr) * 2019-08-07 2021-02-11 Alkermes, Inc. Composés bicycliques fusionnés pour le traitement de la douleur

Also Published As

Publication number Publication date
ZA201005769B (en) 2011-10-26
RU2010137862A (ru) 2012-03-20
MX2010008818A (es) 2010-09-07
CN101910169A (zh) 2010-12-08
KR20100124262A (ko) 2010-11-26
EP2241567A4 (fr) 2011-11-09
AU2009213488A1 (en) 2009-08-20
JPWO2009101917A1 (ja) 2011-06-09
CA2714591A1 (fr) 2009-08-20
US8252810B2 (en) 2012-08-28
WO2009101917A1 (fr) 2009-08-20
EP2241567A1 (fr) 2010-10-20
US20090270369A1 (en) 2009-10-29
IL206875A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
US8252810B2 (en) Bicycloamine derivatives
US20220106331A1 (en) Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators
US10478424B2 (en) [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
US8674096B2 (en) Substituted imidazo[1,5-a]quinoxalin-4-ones as phosphodiesterase 9 inhibitors
CA2894298C (fr) Composes de dihydroisoquinolinone substitue
AU2003214503B2 (en) Tropane derivatives as CCR5 modulators
US9006177B2 (en) Fused tricyclic compounds as adenosine receptor antagonist
US8822448B2 (en) Pyrazoloquinoline compound
US20230121952A1 (en) Compounds
CA3016370A1 (fr) Derives de pyrrolidine spiro-fusionnes en tant qu&#39;inhibiteurs des enzymes de desubiquitination (dub)
JP5916739B2 (ja) ６，７−ジヒドロイミダゾ［２，１−ｂ］［１，３］オキサジン化合物
US9345709B2 (en) 1,5-naphthyridine derivatives and MELK inhibitors containing the same
US20090318690A1 (en) Benzisoxazole Compound
US9034866B2 (en) Tricyclic compounds and methods of use therefor
WO2014072930A2 (fr) Dérivés pyridine fondus, en tant qu&#39;agents antibactériens
WO2018109271A1 (fr) Nouveaux inhibiteurs de bromodomaines

Legal Events

Date Code Title Description
AS Assignment

Owner name: EISAI R&D MANAGEMENT CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OZAKI, FUMIHIRO;SOEJIMA, MOTOHIRO;ISHIDA, TASUKU;AND OTHERS;SIGNING DATES FROM 20100714 TO 20100721;REEL/FRAME:024821/0489

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION